<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Aging Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Aging Neurosci</journal-id>
<journal-id journal-id-type="publisher-id">Front. Aging Neurosci.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Aging Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="epub">1663-4365</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32116645</article-id>
<article-id pub-id-type="pmc">7010934</article-id>
<article-id pub-id-type="doi">10.3389/fnagi.2020.00003</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Peripheral Routes to Neurodegeneration: Passing Through the Blood–Brain Barrier</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Giannoni</surname>
<given-names>Patrizia</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/121440/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Claeysen</surname>
<given-names>Sylvie</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/121271/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Noe</surname>
<given-names>Francesco</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/649064/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Marchi</surname>
<given-names>Nicola</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/263442/overview" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Laboratoire CHROME (EA 7352), Université de Nîmes</institution>, <addr-line>Nîmes</addr-line>, <country>France</country></aff>
<aff id="aff2"><sup>2</sup><institution>CNRS, INSERM U1191, Institut de Génomique Fonctionnelle, University of Montpellier</institution>, <addr-line>Montpellier</addr-line>, <country>France</country></aff>
<aff id="aff3"><sup>3</sup><institution>HiLIFE – Neuroscience Center, University of Helsinki</institution>, <addr-line>Helsinki</addr-line>, <country>Finland</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Daniel Ortuño-Sahagún, Universidad de Guadalajara, Mexico</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Annadora Bruce-Keller, Pennington Biomedical Research Center, United States; Berislav Zlokovic, University of Southern California, United States</p>
</fn>
<corresp id="c001">*Correspondence: Nicola Marchi, <email>nicola.marchi@igf.cnrs.fr</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>04</day>
<month>2</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>12</volume>
<elocation-id>3</elocation-id>
<history>
<date date-type="received">
<day>30</day>
<month>7</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>08</day>
<month>1</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2020 Giannoni, Claeysen, Noe and Marchi.</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>Giannoni, Claeysen, Noe and Marchi</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>A bidirectional crosstalk between peripheral players of immunity and the central nervous system (CNS) exists. Hence, blood–brain barrier (BBB) breakdown is emerging as a participant mechanism of dysregulated peripheral–CNS interplay, promoting diseases. Here, we examine the implication of BBB damage in neurodegeneration, linking it to peripheral brain-directed autoantibodies and gut–brain axis mechanisms. As BBB breakdown is a factor contributing to, or even anticipating, neuronal dysfunction(s), we here identify contemporary pharmacological strategies that could be exploited to repair the BBB in disease conditions. Developing neurovascular, add on, therapeutic strategies may lead to a more efficacious pre-clinical to clinical transition with the goal of curbing the progression of neurodegeneration.</p>
</abstract>
<kwd-group>
<kwd>blood–brain barrier</kwd>
<kwd>neurodegeneration</kwd>
<kwd>peripheral immunity</kwd>
<kwd>traumatic brain injury</kwd>
<kwd>status epilepticus</kwd>
<kwd>autoantibodies</kwd>
<kwd>gut–brain axis</kwd>
<kwd>inflammation</kwd>
</kwd-group>
<counts>
<fig-count count="2"></fig-count>
<table-count count="2"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="185"></ref-count>
<page-count count="14"></page-count>
<word-count count="0"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="S1">
<title>Brain Barriers’ Paths, Leaks, and Neurodegeneration</title>
<p>The term neurodegenerative describes a progressive deterioration of the central nervous system (CNS) that is frequently associated with abnormal accumulation of proteins. Importantly, neurofibrillary tau-protein tangles are not only a major sign of Alzheimer’s disease (AD) but are reported in temporal lobe epilepsy and post-traumatic encephalopathies (<xref ref-type="bibr" rid="B157">Tai et al., 2016</xref>). Among the emerging disease mechanisms, a peripheral–CNS pathological interplay is proposed to contribute to the neurodegenerative process (<xref ref-type="bibr" rid="B90">Marchi et al., 2014</xref>; <xref ref-type="bibr" rid="B39">Engelhardt et al., 2017</xref>; <xref ref-type="bibr" rid="B41">Fung et al., 2017</xref>; <xref ref-type="bibr" rid="B121">Pavlov and Tracey, 2017</xref>; <xref ref-type="bibr" rid="B126">Prinz and Priller, 2017</xref>; <xref ref-type="bibr" rid="B73">Le Page et al., 2018</xref>). Accordingly, harmful events occurring at the cerebrovascular interface are being examined as key determinants partaking to or even preceding neurodegeneration (<xref ref-type="bibr" rid="B184">Zlokovic, 2011</xref>; <xref ref-type="bibr" rid="B108">Nation et al., 2019</xref>; <xref ref-type="bibr" rid="B156">Sweeney et al., 2019</xref>). At the cerebrovasculature, specialized endothelial cells, mural cells, and astroglia constructs (<xref ref-type="bibr" rid="B1">Abbott et al., 2010</xref>; <xref ref-type="bibr" rid="B42">Giannoni et al., 2018</xref>; <xref ref-type="bibr" rid="B156">Sweeney et al., 2019</xref>) provide physical and biological properties governing the homeostatic–immune interactions between peripheral blood cells, or molecules, and brain neuroglia. The physiological parenchymal milieu composition ensures a healthy neuronal transmission, attainable because of the tightness of the blood–brain barrier (BBB; <xref ref-type="bibr" rid="B183">Zlokovic, 2008</xref>; <xref ref-type="bibr" rid="B42">Giannoni et al., 2018</xref>; <xref ref-type="bibr" rid="B108">Nation et al., 2019</xref>). At the pial arterial and venous level, the cerebrovasculature is permissive to blood cells or molecules, while it becomes impermeable at the arteriole–capillary level where barriers’ properties are fully established (<xref ref-type="bibr" rid="B1">Abbott et al., 2010</xref>). BBB vessels also contribute to cerebrospinal and interstitial fluid movements and the elimination of waste products from the interstitial and perivascular spaces (<xref ref-type="bibr" rid="B111">Noé and Marchi, 2019</xref>).</p>
<p>It is increasingly recognized that a BBB pathological imprint can provoke a brain pro-inflammatory disequilibrium sufficient to modify neuronal activity in the long term (<xref ref-type="bibr" rid="B86">Marchi et al., 2007</xref>, <xref ref-type="bibr" rid="B90">2014</xref>; <xref ref-type="bibr" rid="B108">Nation et al., 2019</xref>). Vascular-dependent mechanisms of neurodegeneration can rapidly elicit as a consequence of peripheral infections, head trauma, ischemic stroke, or status epilepticus (<xref ref-type="fig" rid="F1">Figure 1</xref>; <xref ref-type="bibr" rid="B108">Nation et al., 2019</xref>; <xref ref-type="bibr" rid="B156">Sweeney et al., 2019</xref>). These are risk factors for the development of long-term neurodegenerative sequelae and encephalopathies (e.g., post-concussion or head trauma-related chronic traumatic encephalopathy, CTE), cerebral amyloid angiopathy (CAA), AD, and epilepsy. Under conditions of increased BBB permeability, an aberrant bidirectional exchange between the neurovascular unit and the peripheral blood occurs, compounding to neurodegenerative modifications (<xref ref-type="fig" rid="F1">Figure 1</xref>; <xref ref-type="bibr" rid="B90">Marchi et al., 2014</xref>; <xref ref-type="bibr" rid="B39">Engelhardt et al., 2017</xref>; <xref ref-type="bibr" rid="B41">Fung et al., 2017</xref>; <xref ref-type="bibr" rid="B121">Pavlov and Tracey, 2017</xref>; <xref ref-type="bibr" rid="B126">Prinz and Priller, 2017</xref>; <xref ref-type="bibr" rid="B73">Le Page et al., 2018</xref>). Completing a vicious cycle, beta-amyloid deposition in the brain can provoke capillaries dysfunction (<xref ref-type="bibr" rid="B163">Thomas et al., 1996</xref>; <xref ref-type="bibr" rid="B177">Zhang et al., 1997</xref>; <xref ref-type="bibr" rid="B52">Iadecola et al., 1999</xref>; <xref ref-type="bibr" rid="B31">Deane et al., 2003</xref>, <xref ref-type="bibr" rid="B32">2012</xref>; <xref ref-type="bibr" rid="B112">Nortley et al., 2019</xref>). As an example, reactive oxygen species and endothelin-1 production were proposed to elicit vasoconstriction at pericyte locations (<xref ref-type="bibr" rid="B112">Nortley et al., 2019</xref>). A question remains regarding whether the endothelin-1 mechanism can directly drive neurodegeneration.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>The periphery–brain interplay and CNS disease: the neurovascular pathological imprint. <bold>(A)</bold> Proper peripheral–brain segregation under healthy conditions (neurovascular unit, NVU; <italic>blue lines</italic>). <bold>(B)</bold> Pathological insult(s) elicited in the periphery or in the brain (traumatic brain injury, TBI; status epilepticus, SE) converge to NVU damage (e.g., BBB permeability) and neuro-inflammation, leading to temporary or prolonged loss of brain homeostatic control (<bold>B1</bold>, <italic>red arrows</italic>). <bold>(B2)</bold> Under conditions of BBB permeability, concentration gradients favor brain-derived proteins to extravasate into the peripheral blood. Under this condition, a peripheral auto-immune reaction may mount leading to the production of autoantibodies, possibly re-entering into the CNS if BBB damage endures <bold>(B3)</bold>.</p>
</caption>
<graphic xlink:href="fnagi-12-00003-g001"></graphic>
</fig>
</sec>
<sec id="S2">
<title>Autoantibodies and Neurodegeneration: Bad, Good, or Nil?</title>
<p>The communication between the peripheral blood and the brain occurs at preferential cerebrovascular sites (<xref ref-type="bibr" rid="B184">Zlokovic, 2011</xref>; <xref ref-type="bibr" rid="B111">Noé and Marchi, 2019</xref>), e.g., at post-capillary venules or pial vessels, and by a system of lymphatic vessels draining the cerebrospinal and interstitial fluids to cervical lymph nodes (<xref ref-type="bibr" rid="B10">Aspelund et al., 2015</xref>; <xref ref-type="bibr" rid="B79">Louveau et al., 2015a</xref>, <xref ref-type="bibr" rid="B81">b</xref>, <xref ref-type="bibr" rid="B80">2018</xref>). At the intravascular level, moving leukocytes shape a peripheral–brain immune dialog where endothelium activation or permeability, perivascular immune cell homing, and brain entry of immune soluble factors prompt and sustain neuroglia inflammation [<xref ref-type="fig" rid="F1">Figure 1</xref>; see <xref ref-type="bibr" rid="B39">Engelhardt et al. (2017)</xref> and <xref ref-type="bibr" rid="B131">Ransohoff (2016)</xref> for fundamental aspects of endothelial–leukocyte adhesion]. The implication of the cerebrovascular interface to innate and adaptive modalities of immunity is central (<xref ref-type="bibr" rid="B143">Schwartz and Shechter, 2010</xref>; <xref ref-type="bibr" rid="B152">Sommer et al., 2017</xref>). Adaptive immunity to the brain requires T- and B-cell stimulation at extra-CNS lymphatic organs and by professional antigen-presenting cells (<xref ref-type="bibr" rid="B54">Janeway et al., 2001</xref>), thus implying the existence of a peripheral–brain immune dialog, e.g., via the CNS vascular and lymphatic routes (<xref ref-type="bibr" rid="B111">Noé and Marchi, 2019</xref>).</p>
<p>A question exists on whether neurodegeneration may result from autoimmune-like processes (<xref ref-type="table" rid="T1">Table 1</xref>). Contingent to a prolonged or recurrent BBB permeability, specific antigens could exit the brain to reach the bloodstream, mounting a peripheral humoral response. Newly formed brain-directed autoantibodies could be neuropathological upon their entry into the brain across a continuously damaged BBB (<xref ref-type="bibr" rid="B76">Levin et al., 2010</xref>). Importantly, autoantibodies and autoreactive T cells were reported in the cerebrospinal fluid (CSF), sera, as well as in the brain of AD patients and experimental models of disease (<xref ref-type="table" rid="T1">Table 1</xref>; <xref ref-type="bibr" rid="B68">Kronimus et al., 2016</xref>; <xref ref-type="bibr" rid="B176">Wu and Li, 2016</xref>). Anti-Aβ antibodies (Ig type G) correlated with scores of dementia (<xref ref-type="bibr" rid="B175">Wilson et al., 2009</xref>). Intrathecal antibodies against tau filaments were reported in AD patients (<xref ref-type="bibr" rid="B104">Mruthinti et al., 2004</xref>) and were proposed as contributors of disease progression (<xref ref-type="bibr" rid="B14">Bartos et al., 2012</xref>). Anti-tau autoantibodies are not specific to AD as they are increased in patients suffering from other neurodegenerative diseases, e.g., multiple sclerosis (<xref ref-type="bibr" rid="B40">Fialová et al., 2011</xref>).</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Autoantibodies reported in neurodegenerative disease and post-TBI.</p>
</caption>
<table cellpadding="5" cellspacing="5" frame="hsides" rules="groups">
<thead>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Autoantibodies</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neuro- pathology</td>
<td align="left" colspan="1" rowspan="1" valign="top">Stage</td>
<td align="center" colspan="1" rowspan="1" valign="top">Model investigated</td>
<td align="left" colspan="1" rowspan="1" valign="top">Sample</td>
<td align="left" colspan="1" rowspan="1" valign="top">Observed effects</td>
<td align="center" colspan="1" rowspan="1" valign="top">Isotype</td>
<td align="left" colspan="1" rowspan="1" valign="top">References</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Anti-neuronal antibody</td>
<td align="left" colspan="1" rowspan="1" valign="top">TBI</td>
<td align="left" colspan="1" rowspan="1" valign="top">Moderate acute TBI</td>
<td align="center" colspan="1" rowspan="1" valign="top">AM</td>
<td align="left" colspan="1" rowspan="1" valign="top">Serum</td>
<td align="left" colspan="1" rowspan="1" valign="top">–</td>
<td align="center" colspan="1" rowspan="1" valign="top">IgG</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B136">Rudehill et al., 2006</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Anti-neurofilament</td>
<td align="left" colspan="1" rowspan="1" valign="top">AD</td>
<td align="left" colspan="1" rowspan="1" valign="top">Moderate forms of AD</td>
<td align="center" colspan="1" rowspan="1" valign="top">H</td>
<td align="left" colspan="1" rowspan="1" valign="top">Serum, CSF</td>
<td align="left" colspan="1" rowspan="1" valign="top">–</td>
<td align="center" colspan="1" rowspan="1" valign="top">IgG. IgM</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B14">Bartos et al., 2012</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Anti-Aβ</td>
<td align="left" colspan="1" rowspan="1" valign="top">AD</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mild to severe forms of AD, early and late onset</td>
<td align="center" colspan="1" rowspan="1" valign="top">H</td>
<td align="left" colspan="1" rowspan="1" valign="top">Serum, CSF</td>
<td align="left" colspan="1" rowspan="1" valign="top">Suggested to favor Aβ clearance; correlation with global scores of dementia</td>
<td align="center" colspan="1" rowspan="1" valign="top">IgG {IgG2}, Nab</td>
<td align="left" colspan="1" rowspan="1" valign="top"><xref ref-type="bibr" rid="B105">Myagkova et al., 2001</xref>; <xref ref-type="bibr" rid="B15">Bell et al., 2010</xref>; <xref ref-type="bibr" rid="B29">Daneman et al., 2010</xref>; <xref ref-type="bibr" rid="B143">Schwartz and Shechter, 2010</xref>; <xref ref-type="bibr" rid="B9">Armulik et al., 2017</xref>; <xref ref-type="bibr" rid="B61">Kisler et al., 2017</xref>; <xref ref-type="bibr" rid="B137">Rustenhoven et al., 2017</xref>; <xref ref-type="bibr" rid="B152">Sommer et al., 2017</xref>; <xref ref-type="bibr" rid="B103">Montagne et al., 2018</xref>; <xref ref-type="bibr" rid="B109">Nikolakopoulou et al., 2019</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Anti-Tau</td>
<td align="left" colspan="1" rowspan="1" valign="top">AD, TBI</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mid to severe forms of AD</td>
<td align="center" colspan="1" rowspan="1" valign="top">H</td>
<td align="left" colspan="1" rowspan="1" valign="top">Serum, CSF, tissue</td>
<td align="left" colspan="1" rowspan="1" valign="top">Levels correlated with reduced Plaque burden</td>
<td align="center" colspan="1" rowspan="1" valign="top">IgG, Nab</td>
<td align="left" colspan="1" rowspan="1" valign="top"><xref ref-type="bibr" rid="B36">Du et al., 2001</xref>; <xref ref-type="bibr" rid="B174">Weksler et al., 2002</xref>; <xref ref-type="bibr" rid="B104">Mruthinti et al., 2004</xref>; <xref ref-type="bibr" rid="B18">Brettschneider et al., 2005</xref>; <xref ref-type="bibr" rid="B135">Rosenmann et al., 2006</xref>; <xref ref-type="bibr" rid="B46">Gruden et al., 2007</xref>; <xref ref-type="bibr" rid="B47">Gustaw et al., 2008</xref>; <xref ref-type="bibr" rid="B19">Britschgi et al., 2009</xref>; <xref ref-type="bibr" rid="B175">Wilson et al., 2009</xref>; <xref ref-type="bibr" rid="B84">Maftei et al., 2013</xref>; <xref ref-type="bibr" rid="B128">Qu et al., 2014</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Anti-AMPA receptor</td>
<td align="left" colspan="1" rowspan="1" valign="top">AD, TBI</td>
<td align="left" colspan="1" rowspan="1" valign="top">Moderate to severe AD Mild and repetitive concussion in children</td>
<td align="center" colspan="1" rowspan="1" valign="top">H</td>
<td align="left" colspan="1" rowspan="1" valign="top">Serum</td>
<td align="left" colspan="1" rowspan="1" valign="top">Levels increased in moderate and severe dementia</td>
<td align="center" colspan="1" rowspan="1" valign="top">–</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B45">Goryunova et al., 2007</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Anti-NMDA receptor</td>
<td align="left" colspan="1" rowspan="1" valign="top">AD, TBI</td>
<td align="left" colspan="1" rowspan="1" valign="top">Moderate to severe AD and dementia, mild and repetitive concussion</td>
<td align="center" colspan="1" rowspan="1" valign="top">H</td>
<td align="left" colspan="1" rowspan="1" valign="top">Serum</td>
<td align="left" colspan="1" rowspan="1" valign="top">Relationship between autoantibody titers and aging</td>
<td align="center" colspan="1" rowspan="1" valign="top">IgG</td>
<td align="left" colspan="1" rowspan="1" valign="top"><xref ref-type="bibr" rid="B45">Goryunova et al., 2007</xref>; <xref ref-type="bibr" rid="B20">Busse et al., 2014</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Anti-acetyl choline receptor</td>
<td align="left" colspan="1" rowspan="1" valign="top">TBI</td>
<td align="left" colspan="1" rowspan="1" valign="top">TBI to different severity in children</td>
<td align="center" colspan="1" rowspan="1" valign="top">H</td>
<td align="left" colspan="1" rowspan="1" valign="top">Serum</td>
<td align="left" colspan="1" rowspan="1" valign="top">Levels correlate with trauma severity</td>
<td align="center" colspan="1" rowspan="1" valign="top">–</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B153">Sorokina et al., 2011</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Anti-Dopamine</td>
<td align="left" colspan="1" rowspan="1" valign="top">AD</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mid to severe forms of AD</td>
<td align="center" colspan="1" rowspan="1" valign="top">H</td>
<td align="left" colspan="1" rowspan="1" valign="top">Serum</td>
<td align="left" colspan="1" rowspan="1" valign="top">Match to moderate to severe dementia progression</td>
<td align="center" colspan="1" rowspan="1" valign="top">IgG</td>
<td align="left" colspan="1" rowspan="1" valign="top"><xref ref-type="bibr" rid="B105">Myagkova et al., 2001</xref>; <xref ref-type="bibr" rid="B46">Gruden et al., 2007</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Anti-5-HT</td>
<td align="left" colspan="1" rowspan="1" valign="top">AD</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mild to severe forms of AD</td>
<td align="center" colspan="1" rowspan="1" valign="top">H</td>
<td align="left" colspan="1" rowspan="1" valign="top">Serum</td>
<td align="left" colspan="1" rowspan="1" valign="top">Levels increased during mild dementia</td>
<td align="center" colspan="1" rowspan="1" valign="top">–</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B105">Myagkova et al., 2001</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Anti-GFAP</td>
<td align="left" colspan="1" rowspan="1" valign="top">AD, TBI</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pre-senile and senile forms of AD, senile vascular dementia</td>
<td align="center" colspan="1" rowspan="1" valign="top">H</td>
<td align="left" colspan="1" rowspan="1" valign="top">Serum</td>
<td align="left" colspan="1" rowspan="1" valign="top">Relationship between autoantibody titers and aging suggested as a maker of BBB damage</td>
<td align="center" colspan="1" rowspan="1" valign="top">IgG</td>
<td align="left" colspan="1" rowspan="1" valign="top"><xref ref-type="bibr" rid="B158">Tanaka et al., 1989</xref>; <xref ref-type="bibr" rid="B46">Gruden et al., 2007</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Anti-S100β</td>
<td align="left" colspan="1" rowspan="1" valign="top">AD, TBI</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mild to severe AD, senile vascular dementia, repealed acute sub-concussion</td>
<td align="center" colspan="1" rowspan="1" valign="top">H</td>
<td align="left" colspan="1" rowspan="1" valign="top">Serum</td>
<td align="left" colspan="1" rowspan="1" valign="top">Match to moderate–severe dementia progression; relationship between autoantibody titers and aging</td>
<td align="center" colspan="1" rowspan="1" valign="top">IgG</td>
<td align="left" colspan="1" rowspan="1" valign="top"><xref ref-type="bibr" rid="B96">Mecocci et al., 1995</xref>; <xref ref-type="bibr" rid="B46">Gruden et al., 2007</xref>; <xref ref-type="bibr" rid="B87">Marchi et al., 2013</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Anti-microglia</td>
<td align="left" colspan="1" rowspan="1" valign="top">AD</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mid to severe forms of AD</td>
<td align="center" colspan="1" rowspan="1" valign="top">H</td>
<td align="left" colspan="1" rowspan="1" valign="top">CSF</td>
<td align="left" colspan="1" rowspan="1" valign="top">–</td>
<td align="center" colspan="1" rowspan="1" valign="top">IgG</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B95">McRae et al., 2007</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Anti-phospholipid</td>
<td align="left" colspan="1" rowspan="1" valign="top">AD, TBI</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mid cognitive impairment to advanced AD, severe TBI</td>
<td align="center" colspan="1" rowspan="1" valign="top">H</td>
<td align="left" colspan="1" rowspan="1" valign="top">Serum, CSF</td>
<td align="left" colspan="1" rowspan="1" valign="top">Levels correlate with erythrocytes and proteins in CSF</td>
<td align="center" colspan="1" rowspan="1" valign="top">IgG</td>
<td align="left" colspan="1" rowspan="1" valign="top"><xref ref-type="bibr" rid="B93">McIntyre et al., 2007</xref>; <xref ref-type="bibr" rid="B94">McIntyre et al., 2015</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Anti-ceramide</td>
<td align="left" colspan="1" rowspan="1" valign="top">AD</td>
<td align="left" colspan="1" rowspan="1" valign="top">Chronic pathology in TG mice</td>
<td align="center" colspan="1" rowspan="1" valign="top">AM</td>
<td align="left" colspan="1" rowspan="1" valign="top">Serum</td>
<td align="left" colspan="1" rowspan="1" valign="top">Levels correlate with plaque formation</td>
<td align="center" colspan="1" rowspan="1" valign="top">IgG</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B33">Dinkins et al., 2015</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Anti-RAGE</td>
<td align="left" colspan="1" rowspan="1" valign="top">AD</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mild cognitive impairment to severe AD</td>
<td align="center" colspan="1" rowspan="1" valign="top">H</td>
<td align="left" colspan="1" rowspan="1" valign="top">Serum</td>
<td align="left" colspan="1" rowspan="1" valign="top">Relationship with anti-Aβ levels; correlation with global scores of dementia</td>
<td align="center" colspan="1" rowspan="1" valign="top">IgG</td>
<td align="left" colspan="1" rowspan="1" valign="top"><xref ref-type="bibr" rid="B104">Mruthinti et al., 2004</xref>; <xref ref-type="bibr" rid="B175">Wilson et al., 2009</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Anti-ATP synthase</td>
<td align="left" colspan="1" rowspan="1" valign="top">AD</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mild to severe AD</td>
<td align="center" colspan="1" rowspan="1" valign="top">H</td>
<td align="left" colspan="1" rowspan="1" valign="top">Serum</td>
<td align="left" colspan="1" rowspan="1" valign="top">Induced the inhibition of ATP synthesis</td>
<td align="center" colspan="1" rowspan="1" valign="top">IgG</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B167">Vacirca et al., 2012</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Anti-pituitary</td>
<td align="left" colspan="1" rowspan="1" valign="top">TBI</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mild to severe TBI, acute and long-term</td>
<td align="center" colspan="1" rowspan="1" valign="top">H</td>
<td align="left" colspan="1" rowspan="1" valign="top">Serum</td>
<td align="left" colspan="1" rowspan="1" valign="top">Association between antibody positivity and hypopituitarism due to head trauma</td>
<td align="center" colspan="1" rowspan="1" valign="top">IgG</td>
<td align="left" colspan="1" rowspan="1" valign="top"><xref ref-type="bibr" rid="B160">Tanriverdi et al., 2008</xref>; <xref ref-type="bibr" rid="B159">Tanriverdi et al., 2010</xref>; <xref ref-type="bibr" rid="B119">Pani et al., 2019</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Anti-adrenergic receptors</td>
<td align="left" colspan="1" rowspan="1" valign="top">AD</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mild to moderate dementia</td>
<td align="center" colspan="1" rowspan="1" valign="top">H</td>
<td align="left" colspan="1" rowspan="1" valign="top">Serum</td>
<td align="left" colspan="1" rowspan="1" valign="top">Suggested contribution to vascular lesions and increased plaque formation</td>
<td align="center" colspan="1" rowspan="1" valign="top">IgG</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B56">Karczewski et al., 2012</xref>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<attrib>
<italic>AM, data derives from animal models only.</italic>
</attrib>
</table-wrap-foot>
</table-wrap>
<p>The significance of peripheral autoantibodies as biomarkers of neurodegenerative conditions also remains to be established. Autoantibodies against the glutamate receptor <italic>N</italic>-methyl-<sc>D</sc>-aspartate receptor (NMDAR) were detected in plasma of AD patients (<xref ref-type="bibr" rid="B30">Davydova et al., 2007</xref>). Levels of antibodies were shown to correlate with clinical severity, as patients affected by moderate and severe dementia presented a twofold autoantibody increase compared with patients suffering from mild dementia (<xref ref-type="bibr" rid="B30">Davydova et al., 2007</xref>). The presence of autoantibodies against 5-HT was also reported (<xref ref-type="bibr" rid="B105">Myagkova et al., 2001</xref>), with levels increasing during the mild phase of the disease, subsequently reaching a plateau (<xref ref-type="bibr" rid="B105">Myagkova et al., 2001</xref>). Similar findings were reported for autoantibodies directed against the receptor for advanced glycation end products (<xref ref-type="bibr" rid="B175">Wilson et al., 2009</xref>). In a transgenic model of AD, autoantibodies against the sphingolipid ceramide correlated with amyloid plaque increase (<xref ref-type="bibr" rid="B125">Posse de Chaves and Sipione, 2010</xref>; <xref ref-type="bibr" rid="B33">Dinkins et al., 2015</xref>). Autoantibodies against ATP synthase (<xref ref-type="bibr" rid="B167">Vacirca et al., 2012</xref>), α(1)-adrenergic, and the β(2)-adrenergic receptors were also reported (<xref ref-type="bibr" rid="B56">Karczewski et al., 2012</xref>). Autoantibodies against the α(1)-adrenergic and the β(2)-adrenergic receptors may contribute to vascular lesions and increased plaque formation in AD patients (<xref ref-type="bibr" rid="B56">Karczewski et al., 2012</xref>).</p>
<p>Importantly, not all autoantibodies are harmful. Brain-reactive natural autoantibodies (NAbs) are protective (<xref ref-type="bibr" rid="B19">Britschgi et al., 2009</xref>; <xref ref-type="bibr" rid="B58">Kellner et al., 2009</xref>; <xref ref-type="bibr" rid="B34">Dodel et al., 2011</xref>; <xref ref-type="bibr" rid="B12">Bach and Dodel, 2012</xref>). NAbs are mostly IgM and are spontaneously produced. NAbs are polyreactive with low affinity for self-antigens (<xref ref-type="bibr" rid="B22">Casali and Schettino, 1996</xref>). Physiologically, NAbs facilitate phagocytosis of apoptotic cells, inhibit inflammatory pathways, and have a role in maintaining immune tolerance (<xref ref-type="bibr" rid="B38">Elkon and Silverman, 2012</xref>). NAbs to Aβ can inhibit plaque aggregation, block Aβ toxicity, and catalyze Aβ clearance (<xref ref-type="bibr" rid="B78">Lindhagen-Persson et al., 2010</xref>). Immunotherapies using specific, or aspecific, autoantibodies were tested. Bapineuzumab is the humanized form of a monoclonal anti-Aβ antibody targeting the N-terminus of Aβ. In phase II trials, Bapineuzumab administration reduced Aβ plaques in AD brains (<xref ref-type="bibr" rid="B138">Salloway et al., 2009</xref>; <xref ref-type="bibr" rid="B134">Rinne et al., 2010</xref>) and was associated with decreased total and phospho-tau levels in the CSF (<xref ref-type="bibr" rid="B11">Asuni et al., 2007</xref>). Bapineuzumab was, however, discontinued after a phase III trial and showed no beneficial effects on cognitive or functional outcomes (<xref ref-type="bibr" rid="B165">U.S. National Library of Medicine, 2019a</xref>, <xref ref-type="bibr" rid="B166">b</xref>). Aducanumab (BIIB037) is a human monoclonal antibody selectively targeting aggregated Aβ (oligomers and fibrils) (<xref ref-type="bibr" rid="B145">Sevigny et al., 2016</xref>). An Aducanumab phase III trial was terminated as endpoints were not meet. The analysis of a larger data set is ongoing. Tau immunotherapies are also being developed, attenuating or preventing functional impairment in experimental models, as reviewed in <xref ref-type="bibr" rid="B148">Sigurdsson (2018)</xref>.</p>
</sec>
<sec id="S3">
<title>Autoantibodies and Post-Traumatic Encephalopathy</title>
<p>Resulting from repeated head trauma and BBB damage, chronic traumatic encephalopathy (CTE) presents with accumulation of neurofibrillary tau-protein tangles. In TBI subjects, blood and CSF autoantibodies were suggested as etiological components or as possible biomarkers of neurodegeneration (<xref ref-type="bibr" rid="B129">Raad et al., 2014</xref>; <xref ref-type="bibr" rid="B63">Kobeissy, 2015</xref>; <xref ref-type="table" rid="T1">Table 1</xref>). Anti-glial fibrillary acidic protein (GFAP) fragments were found in the sera of TBI patients (<xref ref-type="bibr" rid="B179">Zhang et al., 2014</xref>). Serum autoantibodies against S100B were reported in American football players when repeated sub-concussive events were associated with BBB damage (<xref ref-type="bibr" rid="B87">Marchi et al., 2013</xref>). Autoantibodies against the neuronal α7-subunit of the acetylcholine receptor (<xref ref-type="bibr" rid="B153">Sorokina et al., 2011</xref>) as well as AMPA and NMDA receptors (<xref ref-type="bibr" rid="B45">Goryunova et al., 2007</xref>) were detected in TBI subjects, while IgG autoantibodies to neurons and basal lamina were reported in rat serum following experimental head trauma (<xref ref-type="bibr" rid="B136">Rudehill et al., 2006</xref>). Autoantibodies to the pituitary gland were reported in TBI subjects 3 years after the trauma (<xref ref-type="bibr" rid="B160">Tanriverdi et al., 2008</xref>, <xref ref-type="bibr" rid="B159">2010</xref>). Damage to the pituitary gland is distinctive of the TBI pathology with 20–50% of patients showing some degrees of pituitary dysfunction, which affects growth hormone production (<xref ref-type="bibr" rid="B4">Aimaretti et al., 2005</xref>; <xref ref-type="bibr" rid="B161">Tanriverdi et al., 2006</xref>). An association between anti-pituitary autoantibodies and pituitary dysfunction was reported in patients suffering from mild TBI, including repetitive concussions (<xref ref-type="bibr" rid="B159">Tanriverdi et al., 2010</xref>).</p>
<p>Autoreactive antibodies have been proposed for the treatment of TBI sequelae. The presence of hyper-phosphorylated tau accumulating in neurofibrillary tangles is a characteristic of CTE (<xref ref-type="bibr" rid="B115">Omalu et al., 2010</xref>). Even if phospho-tau is detectable only at low levels acutely after TBI (<xref ref-type="bibr" rid="B151">Smith et al., 2003</xref>; <xref ref-type="bibr" rid="B16">Blennow et al., 2012</xref>; <xref ref-type="bibr" rid="B43">Goldstein et al., 2012</xref>; <xref ref-type="bibr" rid="B85">Mannix et al., 2013</xref>), a specific form of phospho-tau can be produced in response to TBI (<italic>cis</italic> P-tau) (<xref ref-type="bibr" rid="B64">Kondo et al., 2015</xref>). This protein spreads throughout the brain, harming cells and leading to post-traumatic neurodegeneration and dementia. In two animal models of TBI, administration of a monoclonal antibody discriminating between the <italic>cis</italic> and the <italic>trans</italic> forms of the protein and blocking <italic>cis</italic> P-tau prevented the onset of tauopathy and cortical atrophy. These accumulating evidence supports the possible involvement of autoantibodies in post-TBI neurodegenerative conditions, perhaps providing new disease biomarkers and therapeutic entry points.</p>
</sec>
<sec id="S4">
<title>The Gut–Brain Axis and Neurodegeneration: Is There a Barrier Implication?</title>
<p>Here, we discuss a specific framework where alterations of the gut microbiota (GM) could impact BBB permeability, promote neuro-inflammation, and favor neurodegenerative modifications (<xref ref-type="fig" rid="F2">Figure 2</xref>; <xref ref-type="bibr" rid="B17">Braniste et al., 2014</xref>; <xref ref-type="bibr" rid="B24">Cerovic et al., 2019</xref>; <xref ref-type="bibr" rid="B120">Parker et al., 2019</xref>; <xref ref-type="bibr" rid="B172">Wang et al., 2019</xref>). Bacteria, viruses, parasites, and non-pathogenic fungi constitute the intestinal microbiota. These complex communities of microbes colonizing the gastrointestinal tract are major players in health. Modern life and diets have progressively induced changes in the composition of the GM, perhaps for the worse, as this can contribute to chronic illnesses (<xref ref-type="bibr" rid="B82">Lozupone et al., 2012</xref>; <xref ref-type="bibr" rid="B106">Myles, 2014</xref>; <xref ref-type="bibr" rid="B71">Kumar and Forster, 2017</xref>; <xref ref-type="bibr" rid="B146">Shanahan et al., 2017</xref>; <xref ref-type="bibr" rid="B28">Cryan et al., 2019</xref>; <xref ref-type="bibr" rid="B117">Pagliai et al., 2019</xref>; <xref ref-type="bibr" rid="B133">Reza et al., 2019</xref>). Intestinal microbes can influence brain function through a continuous dialog involving the immune, the vascular, and the nervous systems (<xref ref-type="fig" rid="F2">Figure 2</xref>; <xref ref-type="bibr" rid="B142">Schroeder and Bäckhed, 2016</xref>; <xref ref-type="bibr" rid="B26">Cox and Weiner, 2018</xref>; <xref ref-type="bibr" rid="B21">Butler et al., 2019</xref>; <xref ref-type="bibr" rid="B28">Cryan et al., 2019</xref>). Modifications in the composition of the GM was reported in brain disorders, such as autism (<xref ref-type="bibr" rid="B2">Adams et al., 2011</xref>; <xref ref-type="bibr" rid="B55">Kang et al., 2019</xref>), depression (<xref ref-type="bibr" rid="B59">Kelly et al., 2016</xref>; <xref ref-type="bibr" rid="B180">Zheng et al., 2016</xref>), Parkinson’s disease (<xref ref-type="bibr" rid="B140">Scheperjans et al., 2015</xref>; <xref ref-type="bibr" rid="B139">Sampson et al., 2016</xref>), and AD (<xref ref-type="bibr" rid="B23">Cattaneo et al., 2017</xref>; <xref ref-type="bibr" rid="B171">Vogt et al., 2017</xref>; <xref ref-type="bibr" rid="B182">Zhuang et al., 2018</xref>). Intriguingly, the extent of the amyloid pathology in AD mice appears to be dependent of the microbial status, which is specific to the animal housing facility. APP/PS1 mice bred in a germ-free facility displays decreased amyloid plaque number compared to mice housed in non-germ-free conditions (<xref ref-type="bibr" rid="B48">Harach et al., 2017</xref>). Moreover, the administration of broad-spectrum, combinatorial antibiotics to APP/PS1 mice, either during the peri-natal or the adult stage, reduced brain Aβ deposition (<xref ref-type="bibr" rid="B100">Minter et al., 2016</xref>, <xref ref-type="bibr" rid="B99">2017</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Gut–brain axis: communication routes and physiological barriers. A double, peripheral, and brain homeostatic control is performed by the intestinal–epithelial and blood–brain barriers under healthy conditions. Rupture of one barrier (e.g., gut) may impact the other (e.g., brain), with the blood stream and the immune system being the facilitators or the arbitrators of the pathological spread and neuro-inflammation.</p>
</caption>
<graphic xlink:href="fnagi-12-00003-g002"></graphic>
</fig>
<p>Existing reports support the hypothesis of a possible infectious origin of AD. Aβ was proposed as an antimicrobial peptide (<xref ref-type="bibr" rid="B154">Soscia et al., 2010</xref>; <xref ref-type="bibr" rid="B101">Moir et al., 2018</xref>) responding to pathogens (<xref ref-type="bibr" rid="B70">Kumar et al., 2016</xref>; <xref ref-type="bibr" rid="B37">Eimer et al., 2018</xref>). Infectious agents, such as <italic>Chlamydia pneumonia</italic>, <italic>Proprionibacterium acne</italic>, <italic>Helicobacter pylori</italic>, <italic>Porphyromonas gingivalis</italic>, or <italic>spirochetes</italic>, are associated with AD (<xref ref-type="bibr" rid="B65">Kornhuber, 1996</xref>; <xref ref-type="bibr" rid="B13">Balin et al., 1998</xref>; <xref ref-type="bibr" rid="B67">Kountouras et al., 2006</xref>; <xref ref-type="bibr" rid="B97">Miklossy, 2011</xref>; <xref ref-type="bibr" rid="B124">Poole et al., 2015</xref>). A microbial hypothesis is supported by evidence describing the presence of viruses, such as Herpes simplex virus type I, in the brains of AD patients (<xref ref-type="bibr" rid="B77">Lin et al., 2002</xref>; <xref ref-type="bibr" rid="B6">Alonso et al., 2014</xref>; <xref ref-type="bibr" rid="B53">Itzhaki et al., 2016</xref>).</p>
<p>Within the complex interplay between the gut microbiome and the CNS, a role for brain barriers and neuroinflammation is becoming important (<xref ref-type="bibr" rid="B17">Braniste et al., 2014</xref>; <xref ref-type="bibr" rid="B24">Cerovic et al., 2019</xref>; <xref ref-type="bibr" rid="B120">Parker et al., 2019</xref>; <xref ref-type="bibr" rid="B172">Wang et al., 2019</xref>). The impact of the gut microbiome composition on CNS health was reported (<xref ref-type="bibr" rid="B7">Amedei and Boem, 2018</xref>; <xref ref-type="bibr" rid="B25">Chu et al., 2019</xref>; <xref ref-type="bibr" rid="B147">Sherwin et al., 2019</xref>; <xref ref-type="bibr" rid="B170">Virtue et al., 2019</xref>). Recent work demonstrated that GM composition controls BBB development and permeability in mice (<xref ref-type="bibr" rid="B17">Braniste et al., 2014</xref>). In AD, increased gut permeability due to GM dysbiosis was reported during prolonged stress. In this condition, molecules that are normally secluded in the intestine, e.g., inflammatory mediators, bacteria, or bacterial-derived agents, could leak out and reach the peripheral blood. Bacterial DNA, metabolites, or proteins circulating in the blood stream could, in turn, modify BBB permeability (<xref ref-type="bibr" rid="B17">Braniste et al., 2014</xref>; <xref ref-type="bibr" rid="B106">Myles, 2014</xref>; <xref ref-type="bibr" rid="B71">Kumar and Forster, 2017</xref>; <xref ref-type="bibr" rid="B24">Cerovic et al., 2019</xref>; <xref ref-type="bibr" rid="B120">Parker et al., 2019</xref>; <xref ref-type="bibr" rid="B172">Wang et al., 2019</xref>). Existing reports indicated bacterial DNA in human blood with a possibility for brain access (<xref ref-type="bibr" rid="B75">Lelouvier et al., 2016</xref>; <xref ref-type="bibr" rid="B118">Païssé et al., 2016</xref>; <xref ref-type="bibr" rid="B141">Schierwagen et al., 2018</xref>). Brain entry of <italic>P. gingivalis</italic>, a bacterium associated with periodontal disease, has been described (<xref ref-type="bibr" rid="B35">Dominy et al., 2019</xref>). Gingipain inhibitors reduced the bacterial load and the bacteria-induced neuro-inflammation in a mouse model (<xref ref-type="bibr" rid="B35">Dominy et al., 2019</xref>). Among Spirochetes, <italic>Borrelia burgdorferi</italic> is a strain associated with Lyme dementia that could enter the brain. In humans, this specific strain can form biofilms similar to senile plaques. Aβ and bacterial DNA appear as important constituents of these biofilms, suggesting that amyloid plaques may originate in association with or from the spirochetal colonies (<xref ref-type="bibr" rid="B5">Allen, 2016</xref>; <xref ref-type="bibr" rid="B98">Miklossy, 2016</xref>).</p>
<p>These examples highlight the need of tightly regulated intestinal and brain barriers (<xref ref-type="bibr" rid="B130">Rahman et al., 2018</xref>). In AD, a dysbiotic GM may enhance gut permeability and alter BBB integrity, allowing the access of infectious agents or associated molecules into the brain (<xref ref-type="bibr" rid="B91">Martin et al., 2018</xref>). Significantly, intestinal and brain barriers are reactive to analogous pro-inflammatory triggers. Circulating inflammatory cytokines IL-17, interferon-gamma (IFN-γ), and the small intestine epithelium protein zonulin can damage the intestinal–epithelia and BBBs (<xref ref-type="bibr" rid="B130">Rahman et al., 2018</xref>).</p>
</sec>
<sec id="S5">
<title>Gut Microbiota and Autoantibodies: Initial Clues</title>
<p>Hypotheses linking modifications of the GM and production of autoantibodies are emerging (<xref ref-type="bibr" rid="B123">Petta et al., 2018</xref>). Some evidence supports the concept that specific dietary components may affect B-cell maturation and activity, ultimately leading to the formation of autoantibodies (<xref ref-type="bibr" rid="B123">Petta et al., 2018</xref>). Obesity was associated with a systemic pro-inflammatory state, characterized by changes in the frequency of B-cell subpopulation [e.g., reduction of the anti-inflammatory IL-10<sup>+</sup> regulatory B cell (<xref ref-type="bibr" rid="B110">Nishimura et al., 2013</xref>)] and by an increase in autoantibody levels (<xref ref-type="bibr" rid="B66">Kosaraju et al., 2017</xref>). Diets rich in polyunsaturated fatty acid are associated with the suppression of pro-inflammatory responses and a reduction of circulating autoantibodies (<xref ref-type="bibr" rid="B122">Pestka et al., 2014</xref>; <xref ref-type="bibr" rid="B164">Tomasdottir et al., 2014</xref>). Dietary components impact the composition of the gastrointestinal bacterial populations: consumption of prebiotics increases the intestinal levels of <italic>Bifidobacterium</italic> and <italic>Lactobacillus</italic> (<xref ref-type="bibr" rid="B149">Singh et al., 2017</xref>), with a possible link to B-cell differentiation, maturation, and activation (<xref ref-type="bibr" rid="B116">Ouwehand et al., 2002</xref>). Diet can impact autoantibody production, directly by promoting pro-inflammatory conditions and indirectly by altering the GM. In experimental autoimmune encephalomyelitis (EAE) it was demonstrated that the commensal microbiota composition is a pivotal factor for disease development (<xref ref-type="bibr" rid="B74">Lee et al., 2011</xref>) and that modifying the GM impacts the levels of T and B cells or the levels of circulating autoantibodies (<xref ref-type="bibr" rid="B113">Ochoa-Repáraz et al., 2009</xref>, <xref ref-type="bibr" rid="B114">2010</xref>).</p>
</sec>
<sec id="S6">
<title>BBB Repairing Pharmacology: Available Options</title>
<p>The multi-level implication of BBB damage in neurodegenerative disorders has prompted the quest for pharmacological repairing strategies, either directed at the endothelium or by indirect targeting of the cellular players of peripheral and neuro-inflammation. Currently tested drugs are either repurposed or new (<xref ref-type="table" rid="T2">Table 2</xref>). Examples include losartan, an anti-hypertensive molecule acting as an angiotensin II antagonist. Losartan was shown to reduce BBB permeability in a rat model of hypertension (<xref ref-type="bibr" rid="B69">Kucuk et al., 2002</xref>; <xref ref-type="bibr" rid="B57">Kaya et al., 2003</xref>) and following pilocarpine-induced status epilepticus (<xref ref-type="bibr" rid="B50">Hong et al., 2019</xref>). BBB protection by losartan depends on angiotensin receptor type 1 (AT1) blockade. Another drug is rapamycin, a specific inhibitor of the mammalian target of rapamycin (mTOR) pathway. Rapamycin improved cerebrovascular and cognitive function in a mouse model of AD (<xref ref-type="bibr" rid="B168">Van Skike et al., 2018</xref>). Inhibition of mTOR preserved BBB integrity through the upregulation of tight junction proteins and downregulation of matrix metalloproteinase-9. A third option is anakinra, which is the recombinant form of the human IL-1 receptor antagonist (IL1-Ra) that inhibits IL-1α and IL-1β binding to the IL-1 receptor type 1. As inflammation comprises BBB dysfunction, the inhibition of IL-1 as proposed is a strategy enabling cerebrovascular protection (<xref ref-type="bibr" rid="B88">Marchi et al., 2009</xref>, <xref ref-type="bibr" rid="B89">2011</xref>; <xref ref-type="bibr" rid="B169">Vezzani et al., 2011</xref>; <xref ref-type="bibr" rid="B60">Kenney-Jung et al., 2016</xref>). Recent strategies include the development of IL-1Ra molecules fused with a cell-penetrating peptide to enhance brain access (<xref ref-type="bibr" rid="B178">Zhang et al., 2017</xref>). After transient middle cerebral artery occlusion in rats, IL-1Ra-PEP reduced neuro-inflammation and ischemia (<xref ref-type="bibr" rid="B178">Zhang et al., 2017</xref>). The fourth option is IPW-5371, a small molecule blocking the transforming growth factor β receptor (TGFβR) signaling. In a recent study (<xref ref-type="bibr" rid="B144">Senatorov et al., 2019</xref>), IPW reduced hyperexcitability in a mouse model, protecting BBB functions. The activated protein C (APC) therapeutic analog 3K3A-APC is a fifth option. This compound has BBB and neuro-protective properties (<xref ref-type="bibr" rid="B162">Thiyagarajan et al., 2008</xref>; <xref ref-type="bibr" rid="B181">Zhong et al., 2009</xref>; <xref ref-type="bibr" rid="B173">Wang et al., 2016</xref>; <xref ref-type="bibr" rid="B150">Sinha et al., 2018</xref>; <xref ref-type="bibr" rid="B72">Lazic et al., 2019</xref>; <xref ref-type="bibr" rid="B83">Lyden et al., 2019</xref>) and it is in clinical trial for stroke treatment (<xref ref-type="bibr" rid="B83">Lyden et al., 2019</xref>). Next is platelet-derived growth factor subunits BB (PDGF-BB). Following an acute vascular insult, activation of the PDGF receptor beta (PDGFRβ) by PDGF-BB is beneficial, protecting the endothelium–pericyte structures. The latter was reported in mouse models of status epilepticus (<xref ref-type="bibr" rid="B8">Arango-Lievano et al., 2018</xref>) and cerebral ischemia (<xref ref-type="bibr" rid="B92">Marushima et al., 2019</xref>). Conversely, in chronic disease settings (e.g., AD, epilepsy, etc.), activation of PDGFRβ may participate to inflammation (<xref ref-type="bibr" rid="B137">Rustenhoven et al., 2017</xref>; <xref ref-type="bibr" rid="B62">Klement et al., 2019</xref>). Under this circumstance, blocking PDGFRβ signaling by using the tyrosine kinase inhibitor Imatinib could represent an anti-inflammatory strategy (<xref ref-type="bibr" rid="B137">Rustenhoven et al., 2017</xref>; <xref ref-type="bibr" rid="B62">Klement et al., 2019</xref>). In general, reducing PDGFRβ signaling could lead to contrasting effects, e.g., pericyte deficiency and BBB breakdown (<xref ref-type="bibr" rid="B15">Bell et al., 2010</xref>; <xref ref-type="bibr" rid="B29">Daneman et al., 2010</xref>; <xref ref-type="bibr" rid="B9">Armulik et al., 2017</xref>; <xref ref-type="bibr" rid="B61">Kisler et al., 2017</xref>; <xref ref-type="bibr" rid="B103">Montagne et al., 2018</xref>; <xref ref-type="bibr" rid="B109">Nikolakopoulou et al., 2019</xref>) or anti-inflammatory (<xref ref-type="bibr" rid="B137">Rustenhoven et al., 2017</xref>; <xref ref-type="bibr" rid="B62">Klement et al., 2019</xref>), depending on disease stage (acute vs. chronic). Another option, Dexamethasone, is a glucocorticoid effective in the formation and maintenance of endothelial tight junctions (<xref ref-type="bibr" rid="B51">Hue et al., 2015</xref>; <xref ref-type="bibr" rid="B107">Na et al., 2017</xref>). Dexamethasone was proposed to decrease the expression of the Jumonji Domain Containing 3 gene (JMJD3) and metallo-proteinases (MMP-2, MMP-3, and MMP-9). Finally, there is the vascular endothelial growth factor (VEGF). Amyloid accumulation is associated with endothelial apoptosis (<xref ref-type="bibr" rid="B132">Religa et al., 2013</xref>) in Alzheimer’s patients as well as in mouse models. In AD mice, VEGF administration rescued memory deficits by preventing Aβ-induced vascular apoptosis (<xref ref-type="bibr" rid="B132">Religa et al., 2013</xref>). See <xref ref-type="table" rid="T2">Table 2</xref> for complete drug listing, mechanisms and bibliography.</p>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Available molecules exerting BBB repairing and anti-inflammatory effects.</p>
</caption>
<table cellpadding="5" cellspacing="5" frame="hsides" rules="groups">
<thead>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Category</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mechanism(s) of action</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reported effects</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>In vivo</italic> /<italic>in vitro</italic> models</td>
<td align="left" colspan="1" rowspan="1" valign="top">Clinical trials</td>
<td align="left" colspan="1" rowspan="1" valign="top">References</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Losartan</td>
<td align="left" colspan="1" rowspan="1" valign="top">Antihypertensive</td>
<td align="left" colspan="1" rowspan="1" valign="top">Angiotensin II antagonist</td>
<td align="left" colspan="1" rowspan="1" valign="top">Improves barrier function</td>
<td align="left" colspan="1" rowspan="1" valign="top">Rats</td>
<td align="left" colspan="1" rowspan="1" valign="top">Antihypertensive drug</td>
<td align="left" colspan="1" rowspan="1" valign="top"><xref ref-type="bibr" rid="B69">Kucuk et al., 2002</xref>; <xref ref-type="bibr" rid="B57">Kaya et al., 2003</xref>; <xref ref-type="bibr" rid="B50">Hong et al., 2019</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Ripamycin</td>
<td align="left" colspan="1" rowspan="1" valign="top">Immunosuppressant</td>
<td align="left" colspan="1" rowspan="1" valign="top">mTOR antagonist</td>
<td align="left" colspan="1" rowspan="1" valign="top">Improves barrier function, promotes claudin-5</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">Prevention of transplant rejection</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B168">Van Skike et al., 2018</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Anakinra</td>
<td align="left" colspan="1" rowspan="1" valign="top">lnterleukin-1 receptor antagonist</td>
<td align="left" colspan="1" rowspan="1" valign="top">Human interleukin-1 receptor antagonist (IL-IRa)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreases inflammation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Rats</td>
<td align="left" colspan="1" rowspan="1" valign="top">Anti-inflammatory drug currently used against rheumatoid arthritis cryopyrin-associated periodic syndromes (CAPS) and Still’s disease.</td>
<td align="left" colspan="1" rowspan="1" valign="top"><xref ref-type="bibr" rid="B60">Kenney-Jung et al., 2016</xref>; <xref ref-type="bibr" rid="B168">Van Skike et al., 2018</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">IPW</td>
<td align="left" colspan="1" rowspan="1" valign="top">TGFβR1 kinase inhibitor</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition of TGFβR signaling</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduces brain hyperexcitability, indirect BBB repair</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B144">Senatorov et al., 2019</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">3K3A-APC</td>
<td align="left" colspan="1" rowspan="1" valign="top">Activated protein C (APC)</td>
<td align="left" colspan="1" rowspan="1" valign="top">BACE-1 inhibition, activation of protease-activated receptor 1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cytoprotective properties, neovascularization, neurogenesis</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">In clinical trial for ischemic stroke (RHAPSODY)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><xref ref-type="bibr" rid="B162">Thiyagarajan et al., 2008</xref>; <xref ref-type="bibr" rid="B181">Zhong et al., 2009</xref>; <xref ref-type="bibr" rid="B173">Wang et al., 2016</xref>; <xref ref-type="bibr" rid="B150">Sinha et al., 2018</xref>; <xref ref-type="bibr" rid="B72">Lazic et al., 2019</xref>; <xref ref-type="bibr" rid="B83">Lyden et al., 2019</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">PDGF-BB</td>
<td align="left" colspan="1" rowspan="1" valign="top">PDGFRb agonist</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased expression of p-Smad2/3</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ameliorates BBB function</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>In vivo</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B8">Arango-Lievano et al., 2018</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Imatinib</td>
<td align="left" colspan="1" rowspan="1" valign="top">Kinase inhibitor</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibition of PDGFR signaling</td>
<td align="left" colspan="1" rowspan="1" valign="top">anti-inflammatory?</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">Precursor cell lymphoblastic leukemia–lymphoma, dermatofibrosarcoma</td>
<td align="left" colspan="1" rowspan="1" valign="top"><xref ref-type="bibr" rid="B155">Su et al., 2015</xref>; <xref ref-type="bibr" rid="B62">Klement et al., 2019</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Dexamethasone</td>
<td align="left" colspan="1" rowspan="1" valign="top">Glucocorticoid</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased JMJD3 gene expression, suppression of MMP-2, MMP-3, and MMP-9 gene activation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Preserves tight junctions integrity</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>In vitro</italic> BBB model</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inflammatory conditions</td>
<td align="left" colspan="1" rowspan="1" valign="top"><xref ref-type="bibr" rid="B51">Hue et al., 2015</xref>; <xref ref-type="bibr" rid="B107">Na et al., 2017</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Annexin-A1 (ANXA1)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Glucocorticoid anti-inflammatory effector</td>
<td align="left" colspan="1" rowspan="1" valign="top">Binding to FRP2 receptor, inhibition of phospholipase-2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Restores cell polarity, cytoskeleton integrity, and paracellular permeability</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>In vitro</italic> BBB model, Anxa−/− mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top"><xref ref-type="bibr" rid="B27">Cristante et al., 2013</xref>; <xref ref-type="bibr" rid="B127">Purvis et al., 2019</xref>; <xref ref-type="bibr" rid="B185">Zub et al., 2019</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">VEGF</td>
<td align="left" colspan="1" rowspan="1" valign="top">Vascular endothelial growth factor</td>
<td align="left" colspan="1" rowspan="1" valign="top">Prevention of Aβ-induced apoptosis</td>
<td align="left" colspan="1" rowspan="1" valign="top">Improves vascular functions</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B132">Religa et al., 2013</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Tetramethylpyrazine</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cardiovascular</td>
<td align="left" colspan="1" rowspan="1" valign="top">Blocking JAK/STAT signaling</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduces BBB damage</td>
<td align="left" colspan="1" rowspan="1" valign="top">Rats</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B44">Gong et al., 2019</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>S</italic>-nitrosoglutathione</td>
<td align="left" colspan="1" rowspan="1" valign="top">Nitric oxide donor</td>
<td align="left" colspan="1" rowspan="1" valign="top">Suppression of MMP-9 activity</td>
<td align="left" colspan="1" rowspan="1" valign="top">Prevents BBB damage</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B3">Aggarwal et al., 2015</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cannabidiol</td>
<td align="left" colspan="1" rowspan="1" valign="top">Analgesic, anti-inflammatory, antineoplastic</td>
<td align="left" colspan="1" rowspan="1" valign="top">Activation of PPARy and 5-HT<sub>1A</sub> receptors</td>
<td align="left" colspan="1" rowspan="1" valign="top">Prevents BBB damage</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>In vitro</italic> BBB model</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B49">Hind et al., 2016</xref>
</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="S7">
<title>Perspectives and Challenges</title>
<p>The importance of cerebrovascular dysfunction in neurodegenerative disorders is twofold: BBB damage is pathophysiological and it allows a diagnostic window, the latter by exploiting specific proteins that shed from the damaged or vascular wall cells to appear into accessible fluids, e.g., blood or CSF. For instance, by dosing soluble PDGFRβ in CSF and by using dynamic contrast-enhanced magnetic resonance imaging, a recent study demonstrated BBB breakdown as an early biomarker of human cognitive dysfunction (<xref ref-type="bibr" rid="B102">Montagne et al., 2015</xref>; <xref ref-type="bibr" rid="B108">Nation et al., 2019</xref>).</p>
<p>Tackling the complex neurodegenerative puzzle requires a continuous sharpening of pharmacological tools. This is important because no efficacious disease-modifying strategy is available to meaningfully delay or prevent disease progression. The problematics here presented may stem from semantic habits as the term <italic>neuro-</italic> indicates, for most, neurons only. Revisiting nomenclature(s) may benefit, if not legitimize, holistic, and neurovascular approaches to CNS disorders since it is evident that considering neuronal circuits insulated from the influence of glio-vascular cells is excessively reductionist.</p>
</sec>
<sec id="S8">
<title>Author Contributions</title>
<p>NM planned, drafted, and corrected most of the manuscript, including figures and tables. FN wrote the parts on auto-immunity and created the table. SC was responsible for the section “The Gut-Brain Axis and Neurodegeneration: Is There a Barriers’ Implication?”. PG contributed to the section on BBB drugs and to the table, and also contributed to the sections “Gut Microbiota and Autoantibodies Production: Initial Clues” and “References.”</p>
</sec>
<sec id="conf1">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<ack>
<p>This work was supported by the ANR-Epicyte, ANR-HepatoBrain, Era-Net/ANR Neu-Vasc, Fondation de France, FRC, and Muse Grants to NM.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbott</surname><given-names>N. J.</given-names></name><name><surname>Patabendige</surname><given-names>A. A. K.</given-names></name><name><surname>Dolman</surname><given-names>D. E. M.</given-names></name><name><surname>Yusof</surname><given-names>S. R.</given-names></name><name><surname>Begley</surname><given-names>D. J.</given-names></name></person-group> (<year>2010</year>). <article-title>Structure and function of the blood-brain barrier.</article-title>
<source/><italic>Neurobiol. Dis.</italic>
<volume>37</volume>
<fpage>13</fpage>–<lpage>25</lpage>.<pub-id pub-id-type="pmid">19664713</pub-id></mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>J. B.</given-names></name><name><surname>Johansen</surname><given-names>L. J.</given-names></name><name><surname>Powell</surname><given-names>L. D.</given-names></name><name><surname>Quig</surname><given-names>D.</given-names></name><name><surname>Rubin</surname><given-names>R. A.</given-names></name></person-group> (<year>2011</year>). <article-title>Gastrointestinal flora and gastrointestinal status in children with autism–comparisons to typical children and correlation with autism severity.</article-title>
<source/><italic>BMC Gastroenterol.</italic>
<volume>11</volume>:<issue>22</issue>. <pub-id pub-id-type="doi">10.1186/1471-230X-11-22</pub-id>
<pub-id pub-id-type="pmid">21410934</pub-id></mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aggarwal</surname><given-names>A.</given-names></name><name><surname>Khera</surname><given-names>A.</given-names></name><name><surname>Singh</surname><given-names>I.</given-names></name><name><surname>Sandhir</surname><given-names>R.</given-names></name></person-group> (<year>2015</year>). <article-title>S-nitrosoglutathione prevents blood-brain barrier disruption associated with increased matrix metalloproteinase-9 activity in experimental diabetes.</article-title>
<source/><italic>J. Neurochem.</italic>
<volume>132</volume>
<fpage>595</fpage>–<lpage>608</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.12939</pub-id>
<pub-id pub-id-type="pmid">25187090</pub-id></mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aimaretti</surname><given-names>G.</given-names></name><name><surname>Ambrosio</surname><given-names>M. R.</given-names></name><name><surname>Di Somma</surname><given-names>C.</given-names></name><name><surname>Gasperi</surname><given-names>M.</given-names></name><name><surname>Cannavò</surname><given-names>S.</given-names></name><name><surname>Scaroni</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2005</year>). <article-title>Residual pituitary function after brain injury-induced hypopituitarism: a prospective 12-month study.</article-title>
<source/><italic>J. Clin. Endocrinol. Metab.</italic>
<volume>90</volume>
<fpage>6085</fpage>–<lpage>6092</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2005-0504</pub-id>
<pub-id pub-id-type="pmid">16144947</pub-id></mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>H. B.</given-names></name></person-group> (<year>2016</year>). <article-title>Alzheimer’s disease: assessing the role of spirochetes, biofilms, the immune system, and amyloid-β with regard to potential treatment and prevention.</article-title>
<source/><italic>J. Alzheimers Dis.</italic>
<volume>27</volume>
<fpage>1271</fpage>–<lpage>1276</lpage>. <pub-id pub-id-type="doi">10.3233/jad-160388</pub-id>
<pub-id pub-id-type="pmid">27372648</pub-id></mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alonso</surname><given-names>R.</given-names></name><name><surname>Pisa</surname><given-names>D.</given-names></name><name><surname>Marina</surname><given-names>A. I.</given-names></name><name><surname>Morato</surname><given-names>E.</given-names></name><name><surname>Rábano</surname><given-names>A.</given-names></name><name><surname>Carrasco</surname><given-names>L.</given-names></name></person-group> (<year>2014</year>). <article-title>Fungal infection in patients with Alzheimer’s disease.</article-title>
<source/><italic>J. Alzheimers Dis.</italic>
<volume>41</volume>
<fpage>301</fpage>–<lpage>311</lpage>.<pub-id pub-id-type="pmid">24614898</pub-id></mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amedei</surname><given-names>A.</given-names></name><name><surname>Boem</surname><given-names>F.</given-names></name></person-group> (<year>2018</year>). <article-title>I’ve gut a feeling: microbiota impacting the conceptual and experimental perspectives of personalized medicine.</article-title>
<source/><italic>Int. J. Mol. Sci.</italic>
<volume>19</volume>:<issue>E3756</issue>. <pub-id pub-id-type="doi">10.3390/ijms19123756</pub-id>
<pub-id pub-id-type="pmid">30486338</pub-id></mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arango-Lievano</surname><given-names>M.</given-names></name><name><surname>Boussadia</surname><given-names>B.</given-names></name><name><surname>De Terdonck</surname><given-names>L. D. T.</given-names></name><name><surname>Gault</surname><given-names>C.</given-names></name><name><surname>Fontanaud</surname><given-names>P.</given-names></name><name><surname>Lafont</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Topographic reorganization of cerebrovascular mural cells under seizure conditions.</article-title>
<source/><italic>Cell Rep.</italic>
<volume>24</volume>
<fpage>1045</fpage>–<lpage>1059</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2018.03.110</pub-id>
<pub-id pub-id-type="pmid">29694884</pub-id></mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armulik</surname><given-names>A.</given-names></name><name><surname>Genové</surname><given-names>G.</given-names></name><name><surname>Mäe</surname><given-names>M.</given-names></name><name><surname>Nisancioglu</surname><given-names>M. H.</given-names></name><name><surname>Wallgard</surname><given-names>E.</given-names></name><name><surname>Niaudet</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Pericytes regulate the blood-brain barrier.</article-title>
<source/><italic>Nature</italic>
<volume>468</volume>
<fpage>557</fpage>–<lpage>561</lpage>.</mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aspelund</surname><given-names>A.</given-names></name><name><surname>Antila</surname><given-names>S.</given-names></name><name><surname>Proulx</surname><given-names>S. T.</given-names></name><name><surname>Karlsen</surname><given-names>T. V.</given-names></name><name><surname>Karaman</surname><given-names>S.</given-names></name><name><surname>Detmar</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules.</article-title>
<source/><italic>J. Exp. Med.</italic>
<volume>212</volume>
<fpage>991</fpage>–<lpage>999</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20142290</pub-id>
<pub-id pub-id-type="pmid">26077718</pub-id></mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asuni</surname><given-names>A. A.</given-names></name><name><surname>Boutajangout</surname><given-names>A.</given-names></name><name><surname>Quartermain</surname><given-names>D.</given-names></name><name><surname>Sigurdsson</surname><given-names>E. M.</given-names></name></person-group> (<year>2007</year>). <article-title>Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements.</article-title>
<source/><italic>J. Neurosci.</italic>
<volume>27</volume>
<fpage>9115</fpage>–<lpage>9129</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.2361-07.2007</pub-id>
<pub-id pub-id-type="pmid">17715348</pub-id></mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bach</surname><given-names>J.-P.</given-names></name><name><surname>Dodel</surname><given-names>R.</given-names></name></person-group> (<year>2012</year>). <article-title>Naturally occurring autoantibodies against β-Amyloid.</article-title>
<source/><italic>Adv. Exp. Med. Biol.</italic>
<volume>750</volume>
<fpage>91</fpage>–<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4614-3461-0_7</pub-id>
<pub-id pub-id-type="pmid">22903668</pub-id></mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balin</surname><given-names>B. J.</given-names></name><name><surname>Gérard</surname><given-names>H. C.</given-names></name><name><surname>Arking</surname><given-names>E. J.</given-names></name><name><surname>Appelt</surname><given-names>D. M.</given-names></name><name><surname>Branigan</surname><given-names>P. J.</given-names></name><name><surname>Abrams</surname><given-names>J. T.</given-names></name><etal></etal></person-group> (<year>1998</year>). <article-title>Identification and localization of <italic>Chlamydia pneumoniae</italic> in the Alzheimer’s brain.</article-title>
<source/><italic>Med. Microbiol. Immunol.</italic>
<volume>187</volume>
<fpage>23</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="pmid">9749980</pub-id></mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartos</surname><given-names>A.</given-names></name><name><surname>Fialová</surname><given-names>L.</given-names></name><name><surname>Svarcová</surname><given-names>J.</given-names></name><name><surname>Ripova</surname><given-names>D.</given-names></name></person-group> (<year>2012</year>). <article-title>Patients with Alzheimer disease have elevated intrathecal synthesis of antibodies against tau protein and heavy neurofilament.</article-title>
<source/><italic>J. Neuroimmunol.</italic>
<volume>252</volume>
<fpage>100</fpage>–<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneuroim.2012.08.001</pub-id>
<pub-id pub-id-type="pmid">22948089</pub-id></mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>R. D.</given-names></name><name><surname>Winkler</surname><given-names>E. A.</given-names></name><name><surname>Sagare</surname><given-names>A. P.</given-names></name><name><surname>Singh</surname><given-names>I.</given-names></name><name><surname>LaRue</surname><given-names>B.</given-names></name><name><surname>Deane</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging.</article-title>
<source/><italic>Neuron</italic>
<volume>68</volume>
<fpage>409</fpage>–<lpage>427</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2010.09.043</pub-id>
<pub-id pub-id-type="pmid">21040844</pub-id></mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blennow</surname><given-names>K.</given-names></name><name><surname>Hardy</surname><given-names>J.</given-names></name><name><surname>Zetterberg</surname><given-names>H.</given-names></name></person-group> (<year>2012</year>). <article-title>The neuropathology and neurobiology of traumatic brain injury.</article-title>
<source/><italic>Neuron</italic>
<volume>76</volume>
<fpage>886</fpage>–<lpage>899</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2012.11.021</pub-id>
<pub-id pub-id-type="pmid">23217738</pub-id></mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braniste</surname><given-names>V.</given-names></name><name><surname>Al-Asmakh</surname><given-names>M.</given-names></name><name><surname>Kowal</surname><given-names>C.</given-names></name><name><surname>Anuar</surname><given-names>F.</given-names></name><name><surname>Abbaspour</surname><given-names>A.</given-names></name><name><surname>Tóth</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>The gut microbiota influences blood-brain barrier permeability in mice.</article-title>
<source/><italic>Sci. Transl. Med.</italic>
<volume>6</volume>:<issue>263ra158</issue>. <pub-id pub-id-type="doi">10.1126/scitranslmed.3009759</pub-id>
<pub-id pub-id-type="pmid">25411471</pub-id></mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brettschneider</surname><given-names>S.</given-names></name><name><surname>Morgenthaler</surname><given-names>N. G.</given-names></name><name><surname>Teipel</surname><given-names>S. J.</given-names></name><name><surname>Fischer-Schulz</surname><given-names>C.</given-names></name><name><surname>Bürger</surname><given-names>K.</given-names></name><name><surname>Dodel</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2005</year>). <article-title>Decreased serum amyloid beta(1-42) autoantibody levels in Alzheimer’s disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta(1-42) peptide.</article-title>
<source/><italic>Biol. Psychiatry</italic>
<volume>57</volume>
<fpage>813</fpage>–<lpage>816</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2004.12.008</pub-id>
<pub-id pub-id-type="pmid">15820240</pub-id></mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Britschgi</surname><given-names>M.</given-names></name><name><surname>Olin</surname><given-names>C. E.</given-names></name><name><surname>Johns</surname><given-names>H. T.</given-names></name><name><surname>Takeda-Uchimura</surname><given-names>Y.</given-names></name><name><surname>LeMieux</surname><given-names>M. C.</given-names></name><name><surname>Rufibach</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer’s disease.</article-title>
<source/><italic>Proc. Natl. Acad. Sci. U.S.A.</italic>
<volume>106</volume>
<fpage>12145</fpage>–<lpage>12150</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0904866106</pub-id>
<pub-id pub-id-type="pmid">19581601</pub-id></mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busse</surname><given-names>S.</given-names></name><name><surname>Busse</surname><given-names>M.</given-names></name><name><surname>Brix</surname><given-names>B.</given-names></name><name><surname>Probst</surname><given-names>C.</given-names></name><name><surname>Genz</surname><given-names>A.</given-names></name><name><surname>Bogerts</surname><given-names>B.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Seroprevalence of N-methyl-D-aspartate glutamate receptor (NMDA-R) autoantibodies in aging subjects without neuropsychiatric disorders and in dementia patients.</article-title>
<source/><italic>Eur. Arch. Psychiatry Clin. Neurosci.</italic>
<volume>264</volume>
<fpage>545</fpage>–<lpage>550</lpage>. <pub-id pub-id-type="doi">10.1007/s00406-014-0493-9</pub-id>
<pub-id pub-id-type="pmid">24604707</pub-id></mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>M. I.</given-names></name><name><surname>Cryan</surname><given-names>J. F.</given-names></name><name><surname>Dinan</surname><given-names>T. G.</given-names></name></person-group> (<year>2019</year>). <article-title>Man and the microbiome: a new theory of everything?</article-title>
<source/><italic>Annu. Rev. Clin. Psychol.</italic>
<volume>15</volume>
<fpage>371</fpage>–<lpage>398</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-clinpsy-050718-095432</pub-id>
<pub-id pub-id-type="pmid">30786244</pub-id></mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casali</surname><given-names>P.</given-names></name><name><surname>Schettino</surname><given-names>E. W.</given-names></name></person-group> (<year>1996</year>). <article-title>Structure and function of natural antibodies.</article-title>
<source/><italic>Curr. Top. Microbiol. Immunol.</italic>
<volume>210</volume>
<fpage>167</fpage>–<lpage>179</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-642-85226-8_17</pub-id>
<pub-id pub-id-type="pmid">8565555</pub-id></mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cattaneo</surname><given-names>A.</given-names></name><name><surname>Cattane</surname><given-names>N.</given-names></name><name><surname>Galluzzi</surname><given-names>S.</given-names></name><name><surname>Provasi</surname><given-names>S.</given-names></name><name><surname>Lopizzo</surname><given-names>N.</given-names></name><name><surname>Festari</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly.</article-title>
<source/><italic>Neurobiol. Aging</italic>
<volume>49</volume>
<fpage>60</fpage>–<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2016.08.019</pub-id>
<pub-id pub-id-type="pmid">27776263</pub-id></mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerovic</surname><given-names>M.</given-names></name><name><surname>Forloni</surname><given-names>G.</given-names></name><name><surname>Balducci</surname><given-names>C.</given-names></name></person-group> (<year>2019</year>). <article-title>Neuroinflammation and the gut microbiota: possible alternative therapeutic targets to counteract Alzheimer’s disease?</article-title>
<source/><italic>Front. Aging Neurosci.</italic>
<volume>11</volume>:<issue>284</issue>
<pub-id pub-id-type="doi">10.3389/fnagi.2019.00284</pub-id></mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>C.</given-names></name><name><surname>Murdock</surname><given-names>M. H.</given-names></name><name><surname>Jing</surname><given-names>D.</given-names></name><name><surname>Won</surname><given-names>T. H.</given-names></name><name><surname>Chung</surname><given-names>H.</given-names></name><name><surname>Kressel</surname><given-names>A. M.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>The microbiota regulate neuronal function and fear extinction learning.</article-title>
<source/><italic>Nature</italic>
<volume>574</volume>
<fpage>543</fpage>–<lpage>548</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-019-1644-y</pub-id>
<pub-id pub-id-type="pmid">31645720</pub-id></mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>L. M.</given-names></name><name><surname>Weiner</surname><given-names>H. L.</given-names></name></person-group> (<year>2018</year>). <article-title>Microbiota signaling pathways that influence neurologic disease.</article-title>
<source/><italic>Neurother. J. Am. Soc. Exp. Neurother.</italic>
<volume>15</volume>
<fpage>135</fpage>–<lpage>145</lpage>. <pub-id pub-id-type="doi">10.1007/s13311-017-0598-8</pub-id>
<pub-id pub-id-type="pmid">29340928</pub-id></mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cristante</surname><given-names>E.</given-names></name><name><surname>McArthur</surname><given-names>S.</given-names></name><name><surname>Mauro</surname><given-names>C.</given-names></name><name><surname>Maggioli</surname><given-names>E.</given-names></name><name><surname>Romero</surname><given-names>I. A.</given-names></name><name><surname>Wylezinska-Arridge</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Identification of an essential endogenous regulator of blood-brain barrier integrity, and its pathological and therapeutic implications.</article-title>
<source/><italic>Proc. Natl. Acad. Sci. U.S.A.</italic>
<volume>110</volume>
<fpage>832</fpage>–<lpage>841</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1209362110</pub-id>
<pub-id pub-id-type="pmid">23277546</pub-id></mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cryan</surname><given-names>J. F.</given-names></name><name><surname>O’Riordan</surname><given-names>K. J.</given-names></name><name><surname>Cowan</surname><given-names>C. S. M.</given-names></name><name><surname>Sandhu</surname><given-names>K. V.</given-names></name><name><surname>Bastiaanssen</surname><given-names>T. F. S.</given-names></name><name><surname>Boehme</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>The microbiota-gut-brain axis.</article-title>
<source/><italic>Physiol. Rev.</italic>
<volume>99</volume>
<fpage>1877</fpage>–<lpage>2013</lpage>.<pub-id pub-id-type="pmid">31460832</pub-id></mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daneman</surname><given-names>R.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Kebede</surname><given-names>A. A.</given-names></name><name><surname>Barres</surname><given-names>B. A.</given-names></name></person-group> (<year>2010</year>). <article-title>Pericytes are required for blood-brain barrier integrity during embryogenesis.</article-title>
<source/><italic>Nature</italic>
<volume>468</volume>
<fpage>562</fpage>–<lpage>566</lpage>. <pub-id pub-id-type="doi">10.1038/nature09513</pub-id>
<pub-id pub-id-type="pmid">20944625</pub-id></mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davydova</surname><given-names>T. V.</given-names></name><name><surname>Voskresenskaya</surname><given-names>N. I.</given-names></name><name><surname>Fomina</surname><given-names>V. G.</given-names></name><name><surname>Vetrile</surname><given-names>L. A.</given-names></name><name><surname>Doronina</surname><given-names>O. A.</given-names></name></person-group> (<year>2007</year>). <article-title>Induction of autoantibodies to glutamate in patients with Alzheimer’s disease.</article-title>
<source/><italic>Bull. Exp. Biol. Med.</italic>
<volume>143</volume>
<fpage>182</fpage>–<lpage>183</lpage>. <pub-id pub-id-type="doi">10.1007/s10517-007-0044-8</pub-id>
<pub-id pub-id-type="pmid">17970195</pub-id></mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deane</surname><given-names>R.</given-names></name><name><surname>Du Yan</surname><given-names>S.</given-names></name><name><surname>Submamaryan</surname><given-names>R. K.</given-names></name><name><surname>LaRue</surname><given-names>B.</given-names></name><name><surname>Jovanovic</surname><given-names>S.</given-names></name><name><surname>Hogg</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2003</year>). <article-title>RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain.</article-title>
<source/><italic>Nat. Med.</italic>
<volume>9</volume>
<fpage>907</fpage>–<lpage>913</lpage>. <pub-id pub-id-type="doi">10.1038/nm890</pub-id>
<pub-id pub-id-type="pmid">12808450</pub-id></mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deane</surname><given-names>R.</given-names></name><name><surname>Singh</surname><given-names>I.</given-names></name><name><surname>Sagare</surname><given-names>A. P.</given-names></name><name><surname>Bell</surname><given-names>R. D.</given-names></name><name><surname>Ross</surname><given-names>N. T.</given-names></name><name><surname>LaRue</surname><given-names>B.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease.</article-title>
<source/><italic>J. Clin. Invest.</italic>
<volume>122</volume>
<fpage>1377</fpage>–<lpage>1392</lpage>. <pub-id pub-id-type="doi">10.1172/jci58642</pub-id>
<pub-id pub-id-type="pmid">22406537</pub-id></mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinkins</surname><given-names>M. B.</given-names></name><name><surname>Dasgupta</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Zhu</surname><given-names>G.</given-names></name><name><surname>He</surname><given-names>Q.</given-names></name><name><surname>Kong</surname><given-names>J. N.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>The 5XFAD mouse model of Alzheimer’s disease exhibits an age-dependent increase in anti-ceramide IgG and exogenous administration of ceramide further increases anti-ceramide titers and amyloid plaque burden.</article-title>
<source/><italic>J. Alzheimers Dis.</italic>
<volume>46</volume>
<fpage>55</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.3233/jad-150088</pub-id>
<pub-id pub-id-type="pmid">25720409</pub-id></mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodel</surname><given-names>R.</given-names></name><name><surname>Balakrishnan</surname><given-names>K.</given-names></name><name><surname>Keyvani</surname><given-names>K.</given-names></name><name><surname>Deuster</surname><given-names>O.</given-names></name><name><surname>Neff</surname><given-names>F.</given-names></name><name><surname>Andrei-Selmer</surname><given-names>L.-C.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer’s disease.</article-title>
<source/><italic>J. Neurosci.</italic>
<volume>31</volume>
<fpage>5847</fpage>–<lpage>5854</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.4401-10.2011</pub-id><pub-id pub-id-type="pmid">21490226</pub-id></mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dominy</surname><given-names>S. S.</given-names></name><name><surname>Lynch</surname><given-names>C.</given-names></name><name><surname>Ermini</surname><given-names>F.</given-names></name><name><surname>Benedyk</surname><given-names>M.</given-names></name><name><surname>Marczyk</surname><given-names>A.</given-names></name><name><surname>Konradi</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title><italic>Porphyromonas gingivalis</italic> in Alzheimer’s disease brains: evidence for disease causation and treatment with small-molecule inhibitors.</article-title>
<source/><italic>Sci. Adv.</italic>
<volume>5</volume>:<issue>eaau3333</issue>. <pub-id pub-id-type="doi">10.1126/sciadv.aau3333</pub-id>
<pub-id pub-id-type="pmid">30746447</pub-id></mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>Y.</given-names></name><name><surname>Dodel</surname><given-names>R.</given-names></name><name><surname>Hampel</surname><given-names>H.</given-names></name><name><surname>Buerger</surname><given-names>K.</given-names></name><name><surname>Lin</surname><given-names>S.</given-names></name><name><surname>Eastwood</surname><given-names>B.</given-names></name><etal></etal></person-group> (<year>2001</year>). <article-title>Reduced levels of amyloid beta-peptide antibody in Alzheimer disease.</article-title>
<source/><italic>Neurology</italic>
<volume>57</volume>
<fpage>801</fpage>–<lpage>805</lpage>. <pub-id pub-id-type="doi">10.1212/wnl.57.5.801</pub-id>
<pub-id pub-id-type="pmid">11552007</pub-id></mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eimer</surname><given-names>W. A.</given-names></name><name><surname>Vijaya Kumar</surname><given-names>D. K.</given-names></name><name><surname>Navalpur Shanmugam</surname><given-names>N. K.</given-names></name><name><surname>Rodriguez</surname><given-names>A. S.</given-names></name><name><surname>Mitchell</surname><given-names>T.</given-names></name><name><surname>Washicosky</surname><given-names>K. J.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Alzheimer’s disease-associated β-amyloid is rapidly seeded by herpesviridae to protect against brain infection.</article-title>
<source/><italic>Neuron</italic>
<volume>11</volume>
<fpage>56.e3</fpage>–<lpage>63.e3</lpage>.</mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elkon</surname><given-names>K. B.</given-names></name><name><surname>Silverman</surname><given-names>G. J.</given-names></name></person-group> (<year>2012</year>). <article-title>Naturally occurring autoantibodies to apoptotic cells.</article-title>
<source/><italic>Adv. Exp. Med. Biol.</italic>
<volume>750</volume>
<fpage>14</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4614-3461-0_2</pub-id>
<pub-id pub-id-type="pmid">22903663</pub-id></mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engelhardt</surname><given-names>B.</given-names></name><name><surname>Vajkoczy</surname><given-names>P.</given-names></name><name><surname>Weller</surname><given-names>R. O.</given-names></name></person-group> (<year>2017</year>). <article-title>The movers and shapers in immune privilege of the CNS.</article-title>
<source/><italic>Nat. Immunol.</italic>
<volume>18</volume>
<fpage>123</fpage>–<lpage>131</lpage>. <pub-id pub-id-type="doi">10.1038/ni.3666</pub-id>
<pub-id pub-id-type="pmid">28092374</pub-id></mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fialová</surname><given-names>L.</given-names></name><name><surname>Bartos</surname><given-names>A.</given-names></name><name><surname>Svarcová</surname><given-names>J.</given-names></name><name><surname>Malbohan</surname><given-names>I.</given-names></name></person-group> (<year>2011</year>). <article-title>Increased intrathecal high-avidity anti-tau antibodies in patients with multiple sclerosis.</article-title>
<source/><italic>PLoS One</italic>
<volume>6</volume>:<issue>e27476</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0027476</pub-id>
<pub-id pub-id-type="pmid">22140442</pub-id></mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fung</surname><given-names>T. C.</given-names></name><name><surname>Olson</surname><given-names>C. A.</given-names></name><name><surname>Hsiao</surname><given-names>E. Y.</given-names></name></person-group> (<year>2017</year>). <article-title>Interactions between the microbiota, immune and nervous systems in health and disease.</article-title>
<source/><italic>Nat. Neurosci.</italic>
<volume>20</volume>
<fpage>145</fpage>–<lpage>155</lpage>. <pub-id pub-id-type="doi">10.1038/nn.4476</pub-id>
<pub-id pub-id-type="pmid">28092661</pub-id></mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giannoni</surname><given-names>P.</given-names></name><name><surname>Badaut</surname><given-names>J.</given-names></name><name><surname>Dargazanli</surname><given-names>C.</given-names></name><name><surname>De Maudave</surname><given-names>A. F.</given-names></name><name><surname>Klement</surname><given-names>W.</given-names></name><name><surname>Costalat</surname><given-names>V.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>The pericyte-glia interface at the blood-brain barrier.</article-title>
<source/><italic>Clin. Sci. Lond. Engl.</italic>
<volume>14</volume>
<fpage>361</fpage>–<lpage>374</lpage>. <pub-id pub-id-type="doi">10.1042/CS20171634</pub-id>
<pub-id pub-id-type="pmid">29439117</pub-id></mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>L. E.</given-names></name><name><surname>Fisher</surname><given-names>A. M.</given-names></name><name><surname>Tagge</surname><given-names>C. A.</given-names></name><name><surname>Zhang</surname><given-names>X.-L.</given-names></name><name><surname>Velisek</surname><given-names>L.</given-names></name><name><surname>Sullivan</surname><given-names>J. A.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neurotrauma mouse model.</article-title>
<source/><italic>Sci. Transl. Med.</italic>
<volume>4</volume>:<issue>134ra60</issue>.</mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>P.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Zou</surname><given-names>Y.</given-names></name><name><surname>Tian</surname><given-names>Q.</given-names></name><name><surname>Han</surname><given-names>S.</given-names></name><name><surname>Xu</surname><given-names>Z.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Tetramethylpyrazine attenuates blood-brain barrier disruption in ischemia/reperfusion injury through the JAK/STAT signaling pathway.</article-title>
<source/><italic>Eur. J. Pharmacol.</italic>
<volume>854</volume>
<fpage>289</fpage>–<lpage>297</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2019.04.028</pub-id>
<pub-id pub-id-type="pmid">31004602</pub-id></mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goryunova</surname><given-names>A. V.</given-names></name><name><surname>Bazarnaya</surname><given-names>N. A.</given-names></name><name><surname>Sorokina</surname><given-names>E. G.</given-names></name><name><surname>Semenova</surname><given-names>N. Y.</given-names></name><name><surname>Globa</surname><given-names>O. V.</given-names></name><name><surname>Semenova</surname><given-names>Z. B.</given-names></name><etal></etal></person-group> (<year>2007</year>). <article-title>Glutamate receptor autoantibody concentrations in children with chronic post-traumatic headache.</article-title>
<source/><italic>Neurosci. Behav. Physiol.</italic>
<volume>37</volume>
<fpage>761</fpage>–<lpage>764</lpage>. <pub-id pub-id-type="doi">10.1007/s11055-007-0079-3</pub-id>
<pub-id pub-id-type="pmid">17922239</pub-id></mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gruden</surname><given-names>M. A.</given-names></name><name><surname>Davidova</surname><given-names>T. B.</given-names></name><name><surname>Malisauskas</surname><given-names>M.</given-names></name><name><surname>Sewell</surname><given-names>R. D. E.</given-names></name><name><surname>Voskresenskaya</surname><given-names>N. I.</given-names></name><name><surname>Wilhelm</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2007</year>). <article-title>Differential neuroimmune markers to the onset of Alzheimer’s disease neurodegeneration and dementia: autoantibodies to Abeta((25-35)) oligomers, S100b and neurotransmitters.</article-title>
<source/><italic>J. Neuroimmunol.</italic>
<volume>186</volume>
<fpage>181</fpage>–<lpage>192</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneuroim.2007.03.023</pub-id>
<pub-id pub-id-type="pmid">17477976</pub-id></mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gustaw</surname><given-names>K. A.</given-names></name><name><surname>Garrett</surname><given-names>M. R.</given-names></name><name><surname>Lee</surname><given-names>H.-G.</given-names></name><name><surname>Castellani</surname><given-names>R. J.</given-names></name><name><surname>Zagorski</surname><given-names>M. G.</given-names></name><name><surname>Prakasam</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Antigen-antibody dissociation in Alzheimer disease: a novel approach to diagnosis.</article-title>
<source/><italic>J. Neurochem.</italic>
<volume>106</volume>
<fpage>1350</fpage>–<lpage>1356</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2008.05477.x</pub-id>
<pub-id pub-id-type="pmid">18485104</pub-id></mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harach</surname><given-names>T.</given-names></name><name><surname>Marungruang</surname><given-names>N.</given-names></name><name><surname>Duthilleul</surname><given-names>N.</given-names></name><name><surname>Cheatham</surname><given-names>V.</given-names></name><name><surname>Mc Coy</surname><given-names>K. D.</given-names></name><name><surname>Frisoni</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota.</article-title>
<source/><italic>Sci. Rep.</italic>
<volume>08</volume>:<issue>41802</issue>.</mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hind</surname><given-names>W. H.</given-names></name><name><surname>England</surname><given-names>T. J.</given-names></name><name><surname>O’Sullivan</surname><given-names>S. E.</given-names></name></person-group> (<year>2016</year>). <article-title>Cannabidiol protects an in vitro model of the blood-brain barrier from oxygen-glucose deprivation via PPARγ and 5-HT1A receptors.</article-title>
<source/><italic>Br. J. Pharmacol.</italic>
<volume>173</volume>
<fpage>815</fpage>–<lpage>825</lpage>. <pub-id pub-id-type="doi">10.1111/bph.13368</pub-id>
<pub-id pub-id-type="pmid">26497782</pub-id></mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>S.</given-names></name><name><surname>JianCheng</surname><given-names>H.</given-names></name><name><surname>JiaWen</surname><given-names>W.</given-names></name><name><surname>ShuQin</surname><given-names>Z.</given-names></name><name><surname>GuiLian</surname><given-names>Z.</given-names></name><name><surname>HaiQin</surname><given-names>W.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Losartan inhibits development of spontaneous recurrent seizures by preventing astrocyte activation and attenuating blood-brain barrier permeability following pilocarpine-induced status epilepticus.</article-title>
<source/><italic>Brain Res. Bull.</italic>
<volume>149</volume>
<fpage>251</fpage>–<lpage>259</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainresbull.2019.05.002</pub-id>
<pub-id pub-id-type="pmid">31077774</pub-id></mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hue</surname><given-names>C. D.</given-names></name><name><surname>Cho</surname><given-names>F. S.</given-names></name><name><surname>Cao</surname><given-names>S.</given-names></name><name><surname>Dale Bass</surname><given-names>C. R.</given-names></name><name><surname>Meaney</surname><given-names>D. F.</given-names></name><name><surname>Morrison</surname><given-names>B.</given-names></name></person-group> (<year>2015</year>). <article-title>Dexamethasone potentiates in vitro blood-brain barrier recovery after primary blast injury by glucocorticoid receptor-mediated upregulation of ZO-1 tight junction protein.</article-title>
<source/><italic>J. Cereb. Blood Flow Metab.</italic>
<volume>35</volume>
<fpage>1191</fpage>–<lpage>1198</lpage>. <pub-id pub-id-type="doi">10.1038/jcbfm.2015.38</pub-id>
<pub-id pub-id-type="pmid">25757751</pub-id></mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iadecola</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Niwa</surname><given-names>K.</given-names></name><name><surname>Eckman</surname><given-names>C.</given-names></name><name><surname>Turner</surname><given-names>S. K.</given-names></name><name><surname>Fischer</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>1999</year>). <article-title>SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein.</article-title>
<source/><italic>Nat. Neurosci.</italic>
<volume>2</volume>
<fpage>157</fpage>–<lpage>161</lpage>. <pub-id pub-id-type="doi">10.1038/5715</pub-id>
<pub-id pub-id-type="pmid">10195200</pub-id></mixed-citation>
</ref>
<ref id="B53">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itzhaki</surname><given-names>R. F.</given-names></name><name><surname>Lathe</surname><given-names>R.</given-names></name><name><surname>Balin</surname><given-names>B. J.</given-names></name><name><surname>Ball</surname><given-names>M. J.</given-names></name><name><surname>Bearer</surname><given-names>E. L.</given-names></name><name><surname>Braak</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Microbes and Alzheimer’s disease.</article-title>
<source/><italic>J. Alzheimers Dis.</italic>
<volume>51</volume>
<fpage>979</fpage>–<lpage>984</lpage>.<pub-id pub-id-type="pmid">26967229</pub-id></mixed-citation>
</ref>
<ref id="B54">
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Janeway</surname><given-names>C. A.</given-names></name><name><surname>Travers</surname><given-names>P.</given-names></name><name><surname>Walport</surname><given-names>M.</given-names></name><name><surname>Shlomchik</surname><given-names>M. J.</given-names><suffix>Jr.</suffix></name></person-group> (<year>2001</year>). <source/><italic>Immunobiology</italic>, <edition>5th Edn</edition>
<publisher-loc>New York, NY</publisher-loc>: <publisher-name>Garland Science</publisher-name>.</mixed-citation>
</ref>
<ref id="B55">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>D.-W.</given-names></name><name><surname>Adams</surname><given-names>J. B.</given-names></name><name><surname>Coleman</surname><given-names>D. M.</given-names></name><name><surname>Pollard</surname><given-names>E. L.</given-names></name><name><surname>Maldonado</surname><given-names>J.</given-names></name><name><surname>McDonough-Means</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Long-term benefit of microbiota transfer therapy on autism symptoms and gut microbiota.</article-title>
<source/><italic>Sci. Rep.</italic>
<volume>9</volume>:<issue>5821</issue>. <pub-id pub-id-type="doi">10.1038/s41598-019-42183-0</pub-id>
<pub-id pub-id-type="pmid">30967657</pub-id></mixed-citation>
</ref>
<ref id="B56">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karczewski</surname><given-names>P.</given-names></name><name><surname>Hempel</surname><given-names>P.</given-names></name><name><surname>Kunze</surname><given-names>R.</given-names></name><name><surname>Bimmler</surname><given-names>M.</given-names></name></person-group> (<year>2012</year>). <article-title>Agonistic autoantibodies to the α(1) -adrenergic receptor and the β(2) -adrenergic receptor in Alzheimer’s and vascular dementia.</article-title>
<source/><italic>Scand. J. Immunol.</italic>
<volume>75</volume>
<fpage>524</fpage>–<lpage>530</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-3083.2012.02684.x</pub-id>
<pub-id pub-id-type="pmid">22260197</pub-id></mixed-citation>
</ref>
<ref id="B57">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaya</surname><given-names>M.</given-names></name><name><surname>Kalayci</surname><given-names>R.</given-names></name><name><surname>Küçük</surname><given-names>M.</given-names></name><name><surname>Arican</surname><given-names>N.</given-names></name><name><surname>Elmas</surname><given-names>I.</given-names></name><name><surname>Kudat</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2003</year>). <article-title>Effect of losartan on the blood-brain barrier permeability in diabetic hypertensive rats.</article-title>
<source/><italic>Life Sci.</italic>
<volume>73</volume>
<fpage>3235</fpage>–<lpage>3244</lpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2003.06.014</pub-id>
<pub-id pub-id-type="pmid">14561528</pub-id></mixed-citation>
</ref>
<ref id="B58">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kellner</surname><given-names>A.</given-names></name><name><surname>Matschke</surname><given-names>J.</given-names></name><name><surname>Bernreuther</surname><given-names>C.</given-names></name><name><surname>Moch</surname><given-names>H.</given-names></name><name><surname>Ferrer</surname><given-names>I.</given-names></name><name><surname>Glatzel</surname><given-names>M.</given-names></name></person-group> (<year>2009</year>). <article-title>Autoantibodies against beta-amyloid are common in Alzheimer’s disease and help control plaque burden.</article-title>
<source/><italic>Ann. Neurol.</italic>
<volume>65</volume>
<fpage>24</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1002/ana.21475</pub-id>
<pub-id pub-id-type="pmid">19194878</pub-id></mixed-citation>
</ref>
<ref id="B59">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>J. R.</given-names></name><name><surname>Borre</surname><given-names>Y.</given-names></name><name><surname>O’ Brien</surname><given-names>C.</given-names></name><name><surname>Patterson</surname><given-names>E.</given-names></name><name><surname>El Aidy</surname><given-names>S.</given-names></name><name><surname>Deane</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Transferring the blues: depression-associated gut microbiota induces neurobehavioural changes in the rat.</article-title>
<source/><italic>J. Psychiatr. Res.</italic>
<volume>82</volume>
<fpage>109</fpage>–<lpage>118</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpsychires.2016.07.019</pub-id>
<pub-id pub-id-type="pmid">27491067</pub-id></mixed-citation>
</ref>
<ref id="B60">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenney-Jung</surname><given-names>D. L.</given-names></name><name><surname>Vezzani</surname><given-names>A.</given-names></name><name><surname>Kahoud</surname><given-names>R. J.</given-names></name><name><surname>LaFrance-Corey</surname><given-names>R. G.</given-names></name><name><surname>Ho</surname><given-names>M.-L.</given-names></name><name><surname>Muskardin</surname><given-names>T. W.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Febrile infection-related epilepsy syndrome treated with anakinra.</article-title>
<source/><italic>Ann. Neurol.</italic>
<volume>80</volume>
<fpage>939</fpage>–<lpage>945</lpage>. <pub-id pub-id-type="doi">10.1002/ana.24806</pub-id>
<pub-id pub-id-type="pmid">27770579</pub-id></mixed-citation>
</ref>
<ref id="B61">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kisler</surname><given-names>K.</given-names></name><name><surname>Nelson</surname><given-names>A. R.</given-names></name><name><surname>Rege</surname><given-names>S. V.</given-names></name><name><surname>Ramanathan</surname><given-names>A.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Ahuja</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Pericyte degeneration leads to neurovascular uncoupling and limits oxygen supply to brain.</article-title>
<source/><italic>Nat. Neurosci.</italic>
<volume>20</volume>
<fpage>406</fpage>–<lpage>416</lpage>. <pub-id pub-id-type="doi">10.1038/nn.4489</pub-id>
<pub-id pub-id-type="pmid">28135240</pub-id></mixed-citation>
</ref>
<ref id="B62">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klement</surname><given-names>W.</given-names></name><name><surname>Blaquiere</surname><given-names>M.</given-names></name><name><surname>Zub</surname><given-names>E.</given-names></name><name><surname>deBock</surname><given-names>F.</given-names></name><name><surname>Boux</surname><given-names>F.</given-names></name><name><surname>Barbier</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>A pericyte-glia scarring develops at the leaky capillaries in the hippocampus during seizure activity.</article-title>
<source/><italic>Epilepsia</italic>
<volume>60</volume>
<fpage>1399</fpage>–<lpage>1411</lpage>. <pub-id pub-id-type="doi">10.1111/epi.16019</pub-id>
<pub-id pub-id-type="pmid">31135065</pub-id></mixed-citation>
</ref>
<ref id="B63">
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kobeissy</surname><given-names>F. H.</given-names></name></person-group> (<year>2015</year>). <source/><italic>Brain Neurotrauma: Molecular, Neuropsychological, and Rehabilitation Aspects.</italic>
<publisher-loc>Boca Raton, FL</publisher-loc>: <publisher-name>CRC Press</publisher-name>.</mixed-citation>
</ref>
<ref id="B64">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>A.</given-names></name><name><surname>Shahpasand</surname><given-names>K.</given-names></name><name><surname>Mannix</surname><given-names>R.</given-names></name><name><surname>Qiu</surname><given-names>J.</given-names></name><name><surname>Moncaster</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>C.-H.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy.</article-title>
<source/><italic>Nature</italic>
<volume>523</volume>
<fpage>431</fpage>–<lpage>436</lpage>. <pub-id pub-id-type="doi">10.1038/nature14658</pub-id>
<pub-id pub-id-type="pmid">26176913</pub-id></mixed-citation>
</ref>
<ref id="B65">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kornhuber</surname><given-names>H. H.</given-names></name></person-group> (<year>1996</year>). <article-title>Propionibacterium acnes in the cortex of patients with Alzheimer’s disease.</article-title>
<source/><italic>Eur. Arch. Psychiatry Clin. Neurosci.</italic>
<volume>246</volume>
<fpage>108</fpage>–<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1007/bf02274902</pub-id>
<pub-id pub-id-type="pmid">9063907</pub-id></mixed-citation>
</ref>
<ref id="B66">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosaraju</surname><given-names>R.</given-names></name><name><surname>Guesdon</surname><given-names>W.</given-names></name><name><surname>Crouch</surname><given-names>M. J.</given-names></name><name><surname>Teague</surname><given-names>H. L.</given-names></name><name><surname>Sullivan</surname><given-names>E. M.</given-names></name><name><surname>Karlsson</surname><given-names>E. A.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>B cell activity is impaired in human and mouse obesity and is responsive to an essential fatty acid upon murine influenza infection.</article-title>
<source/><italic>J. Immunol.</italic>
<volume>198</volume>
<fpage>4738</fpage>–<lpage>4752</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1601031</pub-id>
<pub-id pub-id-type="pmid">28500069</pub-id></mixed-citation>
</ref>
<ref id="B67">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kountouras</surname><given-names>J.</given-names></name><name><surname>Tsolaki</surname><given-names>M.</given-names></name><name><surname>Gavalas</surname><given-names>E.</given-names></name><name><surname>Boziki</surname><given-names>M.</given-names></name><name><surname>Zavos</surname><given-names>C.</given-names></name><name><surname>Karatzoglou</surname><given-names>P.</given-names></name><etal></etal></person-group> (<year>2006</year>). <article-title>Relationship between <italic>Helicobacter pylori</italic> infection and Alzheimer disease.</article-title>
<source/><italic>Neurology</italic>
<volume>66</volume>
<fpage>938</fpage>–<lpage>940</lpage>. <pub-id pub-id-type="doi">10.1212/01.wnl.0000203644.68059.5f</pub-id>
<pub-id pub-id-type="pmid">16567719</pub-id></mixed-citation>
</ref>
<ref id="B68">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kronimus</surname><given-names>Y.</given-names></name><name><surname>Albus</surname><given-names>A.</given-names></name><name><surname>Balzer-Geldsetzer</surname><given-names>M.</given-names></name><name><surname>Straub</surname><given-names>S.</given-names></name><name><surname>Semler</surname><given-names>E.</given-names></name><name><surname>Otto</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Naturally occurring autoantibodies against tau protein are reduced in Parkinson’s disease dementia.</article-title>
<source/><italic>PLoS One</italic>
<volume>11</volume>:<issue>e0164953</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0164953</pub-id>
<pub-id pub-id-type="pmid">27802290</pub-id></mixed-citation>
</ref>
<ref id="B69">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kucuk</surname><given-names>M.</given-names></name><name><surname>Kaya</surname><given-names>M.</given-names></name><name><surname>Kalayci</surname><given-names>R.</given-names></name><name><surname>Cimen</surname><given-names>V.</given-names></name><name><surname>Kudat</surname><given-names>H.</given-names></name><name><surname>Arican</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2002</year>). <article-title>Effects of losartan on the blood-brain barrier permeability in long-term nitric oxide blockade-induced hypertensive rats.</article-title>
<source/><italic>Life Sci.</italic>
<volume>71</volume>
<fpage>937</fpage>–<lpage>946</lpage>. <pub-id pub-id-type="doi">10.1016/s0024-3205(02)01772-1</pub-id>
<pub-id pub-id-type="pmid">12084390</pub-id></mixed-citation>
</ref>
<ref id="B70">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>D. K. V.</given-names></name><name><surname>Choi</surname><given-names>S. H.</given-names></name><name><surname>Washicosky</surname><given-names>K. J.</given-names></name><name><surname>Eimer</surname><given-names>W. A.</given-names></name><name><surname>Tucker</surname><given-names>S.</given-names></name><name><surname>Ghofrani</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease.</article-title>
<source/><italic>Sci. Transl. Med.</italic>
<volume>8</volume>:<issue>340ra72</issue>. <pub-id pub-id-type="doi">10.1126/scitranslmed.aaf1059</pub-id>
<pub-id pub-id-type="pmid">27225182</pub-id></mixed-citation>
</ref>
<ref id="B71">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>N.</given-names></name><name><surname>Forster</surname><given-names>S. C.</given-names></name></person-group> (<year>2017</year>). <article-title>Genome watch: microbiota shuns the modern world.</article-title>
<source/><italic>Nat. Rev. Microbiol.</italic>
<volume>15</volume>
<fpage>710</fpage>–<lpage>710</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro.2017.136</pub-id>
<pub-id pub-id-type="pmid">29081498</pub-id></mixed-citation>
</ref>
<ref id="B72">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazic</surname><given-names>D.</given-names></name><name><surname>Sagare</surname><given-names>A. P.</given-names></name><name><surname>Nikolakopoulou</surname><given-names>A. M.</given-names></name><name><surname>Griffin</surname><given-names>J. H.</given-names></name><name><surname>Vassar</surname><given-names>R.</given-names></name><name><surname>Zlokovic</surname><given-names>B. V.</given-names></name></person-group> (<year>2019</year>). <article-title>3K3A-activated protein C blocks amyloidogenic BACE1 pathway and improves functional outcome in mice.</article-title>
<source/><italic>J. Exp. Med.</italic>
<volume>216</volume>
<fpage>279</fpage>–<lpage>293</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20181035</pub-id>
<pub-id pub-id-type="pmid">30647119</pub-id></mixed-citation>
</ref>
<ref id="B73">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Page</surname><given-names>A.</given-names></name><name><surname>Dupuis</surname><given-names>G.</given-names></name><name><surname>Frost</surname><given-names>E. H.</given-names></name><name><surname>Larbi</surname><given-names>A.</given-names></name><name><surname>Pawelec</surname><given-names>G.</given-names></name><name><surname>Witkowski</surname><given-names>J. M.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Role of the peripheral innate immune system in the development of Alzheimer’s disease.</article-title>
<source/><italic>Exp. Gerontol.</italic>
<volume>01</volume>
<fpage>59</fpage>–<lpage>66</lpage>.</mixed-citation>
</ref>
<ref id="B74">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>Y. K.</given-names></name><name><surname>Menezes</surname><given-names>J. S.</given-names></name><name><surname>Umesaki</surname><given-names>Y.</given-names></name><name><surname>Mazmanian</surname><given-names>S. K.</given-names></name></person-group> (<year>2011</year>). <article-title>Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis.</article-title>
<source/><italic>Proc. Natl. Acad. Sci. U.S.A.</italic>
<volume>108</volume>(<issue>Suppl. 1</issue>), <fpage>4615</fpage>–<lpage>4622</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1000082107</pub-id>
<pub-id pub-id-type="pmid">20660719</pub-id></mixed-citation>
</ref>
<ref id="B75">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lelouvier</surname><given-names>B.</given-names></name><name><surname>Servant</surname><given-names>F.</given-names></name><name><surname>Païssé</surname><given-names>S.</given-names></name><name><surname>Brunet</surname><given-names>A.-C.</given-names></name><name><surname>Benyahya</surname><given-names>S.</given-names></name><name><surname>Serino</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Changes in blood microbiota profiles associated with liver fibrosis in obese patients: a pilot analysis.</article-title>
<source/><italic>Hepatology</italic>
<volume>64</volume>
<fpage>2015</fpage>–<lpage>2027</lpage>. <pub-id pub-id-type="doi">10.1002/hep.28829</pub-id>
<pub-id pub-id-type="pmid">27639192</pub-id></mixed-citation>
</ref>
<ref id="B76">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>E. C.</given-names></name><name><surname>Acharya</surname><given-names>N. K.</given-names></name><name><surname>Han</surname><given-names>M.</given-names></name><name><surname>Zavareh</surname><given-names>S. B.</given-names></name><name><surname>Sedeyn</surname><given-names>J. C.</given-names></name><name><surname>Venkataraman</surname><given-names>V.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Brain-reactive autoantibodies are nearly ubiquitous in human sera and may be linked to pathology in the context of blood-brain barrier breakdown.</article-title>
<source/><italic>Brain Res.</italic>
<volume>1345</volume>
<fpage>221</fpage>–<lpage>232</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2010.05.038</pub-id>
<pub-id pub-id-type="pmid">20546711</pub-id></mixed-citation>
</ref>
<ref id="B77">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>W.-R.</given-names></name><name><surname>Wozniak</surname><given-names>M. A.</given-names></name><name><surname>Cooper</surname><given-names>R. J.</given-names></name><name><surname>Wilcock</surname><given-names>G. K.</given-names></name><name><surname>Itzhaki</surname><given-names>R. F.</given-names></name></person-group> (<year>2002</year>). <article-title>Herpesviruses in brain and Alzheimer’s disease.</article-title>
<source/><italic>J. Pathol.</italic>
<volume>197</volume>
<fpage>395</fpage>–<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1002/path.1127</pub-id>
<pub-id pub-id-type="pmid">12115887</pub-id></mixed-citation>
</ref>
<ref id="B78">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindhagen-Persson</surname><given-names>M.</given-names></name><name><surname>Brännström</surname><given-names>K.</given-names></name><name><surname>Vestling</surname><given-names>M.</given-names></name><name><surname>Steinitz</surname><given-names>M.</given-names></name><name><surname>Olofsson</surname><given-names>A.</given-names></name></person-group> (<year>2010</year>). <article-title>Amyloid-β oligomer specificity mediated by the IgM isotype–implications for a specific protective mechanism exerted by endogenous auto-antibodies.</article-title>
<source/><italic>PLoS One</italic>
<volume>5</volume>:<issue>e13928</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0013928</pub-id>
<pub-id pub-id-type="pmid">21085663</pub-id></mixed-citation>
</ref>
<ref id="B79">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louveau</surname><given-names>A.</given-names></name><name><surname>Harris</surname><given-names>T. H.</given-names></name><name><surname>Kipnis</surname><given-names>J.</given-names></name></person-group> (<year>2015a</year>). <article-title>Revisiting the mechanisms of CNS immune privilege.</article-title>
<source/><italic>Trends Immunol.</italic>
<volume>36</volume>
<fpage>569</fpage>–<lpage>577</lpage>. <pub-id pub-id-type="doi">10.1016/j.it.2015.08.006</pub-id>
<pub-id pub-id-type="pmid">26431936</pub-id></mixed-citation>
</ref>
<ref id="B80">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louveau</surname><given-names>A.</given-names></name><name><surname>Herz</surname><given-names>J.</given-names></name><name><surname>Alme</surname><given-names>M. N.</given-names></name><name><surname>Salvador</surname><given-names>A. F.</given-names></name><name><surname>Dong</surname><given-names>M. Q.</given-names></name><name><surname>Viar</surname><given-names>K. E.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature.</article-title>
<source/><italic>Nat. Neurosci.</italic>
<volume>21</volume>
<fpage>1380</fpage>–<lpage>1391</lpage>. <pub-id pub-id-type="doi">10.1038/s41593-018-0227-9</pub-id>
<pub-id pub-id-type="pmid">30224810</pub-id></mixed-citation>
</ref>
<ref id="B81">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louveau</surname><given-names>A.</given-names></name><name><surname>Smirnov</surname><given-names>I.</given-names></name><name><surname>Keyes</surname><given-names>T. J.</given-names></name><name><surname>Eccles</surname><given-names>J. D.</given-names></name><name><surname>Rouhani</surname><given-names>S. J.</given-names></name><name><surname>Peske</surname><given-names>J. D.</given-names></name><etal></etal></person-group> (<year>2015b</year>). <article-title>Structural and functional features of central nervous system lymphatic vessels.</article-title>
<source/><italic>Nature</italic>
<volume>523</volume>
<fpage>337</fpage>–<lpage>341</lpage>. <pub-id pub-id-type="doi">10.1038/nature14432</pub-id>
<pub-id pub-id-type="pmid">26030524</pub-id></mixed-citation>
</ref>
<ref id="B82">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lozupone</surname><given-names>C. A.</given-names></name><name><surname>Stombaugh</surname><given-names>J. I.</given-names></name><name><surname>Gordon</surname><given-names>J. I.</given-names></name><name><surname>Jansson</surname><given-names>J. K.</given-names></name><name><surname>Knight</surname><given-names>R.</given-names></name></person-group> (<year>2012</year>). <article-title>Diversity, stability and resilience of the human gut microbiota.</article-title>
<source/><italic>Nature</italic>
<volume>489</volume>
<fpage>220</fpage>–<lpage>230</lpage>. <pub-id pub-id-type="doi">10.1038/nature11550</pub-id>
<pub-id pub-id-type="pmid">22972295</pub-id></mixed-citation>
</ref>
<ref id="B83">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyden</surname><given-names>P.</given-names></name><name><surname>Pryor</surname><given-names>K. E.</given-names></name><name><surname>Coffey</surname><given-names>C. S.</given-names></name><name><surname>Cudkowicz</surname><given-names>M.</given-names></name><name><surname>Conwit</surname><given-names>R.</given-names></name><name><surname>Jadhav</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Final results of the RHAPSODY trial: a multi-center, phase 2 trial using a continual reassessment method to determine the safety and tolerability of 3K3A-APC, a recombinant variant of human activated protein C, in combination with tissue plasminogen activator, mechanical thrombectomy or both in moderate to severe acute ischemic stroke.</article-title>
<source/><italic>Ann. Neurol.</italic>
<volume>85</volume>
<fpage>125</fpage>–<lpage>136</lpage>. <pub-id pub-id-type="doi">10.1002/ana.25383</pub-id>
<pub-id pub-id-type="pmid">30450637</pub-id></mixed-citation>
</ref>
<ref id="B84">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maftei</surname><given-names>M.</given-names></name><name><surname>Thurm</surname><given-names>F.</given-names></name><name><surname>Schnack</surname><given-names>C.</given-names></name><name><surname>Tumani</surname><given-names>H.</given-names></name><name><surname>Otto</surname><given-names>M.</given-names></name><name><surname>Elbert</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Increased levels of antigen-bound β-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer’s disease patients.</article-title>
<source/><italic>PLoS One</italic>
<volume>8</volume>:<issue>e68996</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0068996</pub-id>
<pub-id pub-id-type="pmid">23874844</pub-id></mixed-citation>
</ref>
<ref id="B85">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mannix</surname><given-names>R.</given-names></name><name><surname>Meehan</surname><given-names>W. P.</given-names></name><name><surname>Mandeville</surname><given-names>J.</given-names></name><name><surname>Grant</surname><given-names>P. E.</given-names></name><name><surname>Gray</surname><given-names>T.</given-names></name><name><surname>Berglass</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Clinical correlates in an experimental model of repetitive mild brain injury.</article-title>
<source/><italic>Ann. Neurol.</italic>
<volume>74</volume>
<fpage>65</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1002/ana.23858</pub-id>
<pub-id pub-id-type="pmid">23922306</pub-id></mixed-citation>
</ref>
<ref id="B86">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchi</surname><given-names>N.</given-names></name><name><surname>Angelov</surname><given-names>L.</given-names></name><name><surname>Masaryk</surname><given-names>T.</given-names></name><name><surname>Fazio</surname><given-names>V.</given-names></name><name><surname>Granata</surname><given-names>T.</given-names></name><name><surname>Hernandez</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2007</year>). <article-title>Seizure-promoting effect of blood-brain barrier disruption.</article-title>
<source/><italic>Epilepsia</italic>
<volume>48</volume>
<fpage>732</fpage>–<lpage>742</lpage>. <pub-id pub-id-type="doi">10.1111/j.1528-1167.2007.00988.x</pub-id>
<pub-id pub-id-type="pmid">17319915</pub-id></mixed-citation>
</ref>
<ref id="B87">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchi</surname><given-names>N.</given-names></name><name><surname>Bazarian</surname><given-names>J. J.</given-names></name><name><surname>Puvenna</surname><given-names>V.</given-names></name><name><surname>Janigro</surname><given-names>M.</given-names></name><name><surname>Ghosh</surname><given-names>C.</given-names></name><name><surname>Zhong</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Consequences of repeated blood-brain barrier disruption in football players.</article-title>
<source/><italic>PLoS One</italic>
<volume>8</volume>:<issue>e56805</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0056805</pub-id>
<pub-id pub-id-type="pmid">23483891</pub-id></mixed-citation>
</ref>
<ref id="B88">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchi</surname><given-names>N.</given-names></name><name><surname>Fan</surname><given-names>Q.</given-names></name><name><surname>Ghosh</surname><given-names>C.</given-names></name><name><surname>Fazio</surname><given-names>V.</given-names></name><name><surname>Bertolini</surname><given-names>F.</given-names></name><name><surname>Betto</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Antagonism of peripheral inflammation reduces the severity of status epilepticus.</article-title>
<source/><italic>Neurobiol. Dis.</italic>
<volume>33</volume>
<fpage>171</fpage>–<lpage>181</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2008.10.002</pub-id>
<pub-id pub-id-type="pmid">19010416</pub-id></mixed-citation>
</ref>
<ref id="B89">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchi</surname><given-names>N.</given-names></name><name><surname>Granata</surname><given-names>T.</given-names></name><name><surname>Freri</surname><given-names>E.</given-names></name><name><surname>Ciusani</surname><given-names>E.</given-names></name><name><surname>Ragona</surname><given-names>F.</given-names></name><name><surname>Puvenna</surname><given-names>V.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Efficacy of anti-inflammatory therapy in a model of acute seizures and in a population of pediatric drug resistant epileptics.</article-title>
<source/><italic>PLoS One</italic>
<volume>6</volume>:<issue>e18200</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0018200</pub-id>
<pub-id pub-id-type="pmid">21464890</pub-id></mixed-citation>
</ref>
<ref id="B90">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchi</surname><given-names>N.</given-names></name><name><surname>Granata</surname><given-names>T.</given-names></name><name><surname>Janigro</surname><given-names>D.</given-names></name></person-group> (<year>2014</year>). <article-title>Inflammatory pathways of seizure disorders.</article-title>
<source/><italic>Trends Neurosci.</italic>
<volume>37</volume>
<fpage>55</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1016/j.tins.2013.11.002</pub-id>
<pub-id pub-id-type="pmid">24355813</pub-id></mixed-citation>
</ref>
<ref id="B91">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>C. R.</given-names></name><name><surname>Osadchiy</surname><given-names>V.</given-names></name><name><surname>Kalani</surname><given-names>A.</given-names></name><name><surname>Mayer</surname><given-names>E. A.</given-names></name></person-group> (<year>2018</year>). <article-title>The brain-gut-microbiome axis.</article-title>
<source/><italic>Cell Mol. Gastroenterol. Hepatol.</italic>
<volume>6</volume>
<fpage>133</fpage>–<lpage>148</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcmgh.2018.04.003</pub-id>
<pub-id pub-id-type="pmid">30023410</pub-id></mixed-citation>
</ref>
<ref id="B92">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marushima</surname><given-names>A.</given-names></name><name><surname>Nieminen</surname><given-names>M.</given-names></name><name><surname>Kremenetskaia</surname><given-names>I.</given-names></name><name><surname>Gianni-Barrera</surname><given-names>R.</given-names></name><name><surname>Woitzik</surname><given-names>J.</given-names></name><name><surname>von Degenfeld</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Balanced single-vector co-delivery of VEGF/PDGF-BB improves functional collateralization in chronic cerebral ischemia.</article-title>
<source/><italic>J. Cereb. Blood Flow Metab.</italic>
<volume>9</volume>:<issue>271678X18818298</issue>. <pub-id pub-id-type="doi">10.1177/0271678X18818298</pub-id>
<pub-id pub-id-type="pmid">30621518</pub-id></mixed-citation>
</ref>
<ref id="B93">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McIntyre</surname><given-names>J. A.</given-names></name><name><surname>Chapman</surname><given-names>J.</given-names></name><name><surname>Shavit</surname><given-names>E.</given-names></name><name><surname>Hamilton</surname><given-names>R. L.</given-names></name><name><surname>Dekosky</surname><given-names>S. T.</given-names></name></person-group> (<year>2007</year>). <article-title>Redox-reactive autoantibodies in Alzheimer’s patients’ cerebrospinal fluids: preliminary studies.</article-title>
<source/><italic>Autoimmunity</italic>
<volume>40</volume>
<fpage>390</fpage>–<lpage>396</lpage>. <pub-id pub-id-type="doi">10.1080/08916930701421020</pub-id>
<pub-id pub-id-type="pmid">17612901</pub-id></mixed-citation>
</ref>
<ref id="B94">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McIntyre</surname><given-names>J. A.</given-names></name><name><surname>Ramsey</surname><given-names>C. J.</given-names></name><name><surname>Gitter</surname><given-names>B. D.</given-names></name><name><surname>Saykin</surname><given-names>A. J.</given-names></name><name><surname>Wagenknecht</surname><given-names>D. R.</given-names></name><name><surname>Hyslop</surname><given-names>P. A.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Antiphospholipid autoantibodies as blood biomarkers for detection of early stage Alzheimer’s disease.</article-title>
<source/><italic>Autoimmunity</italic>
<volume>48</volume>
<fpage>344</fpage>–<lpage>351</lpage>. <pub-id pub-id-type="doi">10.3109/08916934.2015.1008464</pub-id>
<pub-id pub-id-type="pmid">25672931</pub-id></mixed-citation>
</ref>
<ref id="B95">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McRae</surname><given-names>A.</given-names></name><name><surname>Martins</surname><given-names>R. N.</given-names></name><name><surname>Fonte</surname><given-names>J.</given-names></name><name><surname>Kraftsik</surname><given-names>R.</given-names></name><name><surname>Hirt</surname><given-names>L.</given-names></name><name><surname>Miklossy</surname><given-names>J.</given-names></name></person-group> (<year>2007</year>). <article-title>Cerebrospinal fluid antimicroglial antibodies in Alzheimer disease: a putative marker of an ongoing inflammatory process.</article-title>
<source/><italic>Exp. Gerontol.</italic>
<volume>42</volume>
<fpage>355</fpage>–<lpage>363</lpage>. <pub-id pub-id-type="doi">10.1016/j.exger.2006.10.015</pub-id>
<pub-id pub-id-type="pmid">17140756</pub-id></mixed-citation>
</ref>
<ref id="B96">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mecocci</surname><given-names>P.</given-names></name><name><surname>Parnetti</surname><given-names>L.</given-names></name><name><surname>Romano</surname><given-names>G.</given-names></name><name><surname>Scarelli</surname><given-names>A.</given-names></name><name><surname>Chionne</surname><given-names>F.</given-names></name><name><surname>Cecchetti</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>1995</year>). <article-title>Serum anti-GFAP and anti-S100 autoantibodies in brain aging, Alzheimer’s disease and vascular dementia.</article-title>
<source/><italic>J. Neuroimmunol.</italic>
<volume>57</volume>
<fpage>165</fpage>–<lpage>170</lpage>. <pub-id pub-id-type="doi">10.1016/0165-5728(94)00180-v</pub-id>
<pub-id pub-id-type="pmid">7706432</pub-id></mixed-citation>
</ref>
<ref id="B97">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miklossy</surname><given-names>J.</given-names></name></person-group> (<year>2011</year>). <article-title>Alzheimer’s disease - a neurospirochetosis. Analysis of the evidence following Koch’s and Hill’s criteria.</article-title>
<source/><italic>J. Neuroinflamm.</italic>
<volume>8</volume>:<issue>90</issue>. <pub-id pub-id-type="doi">10.1186/1742-2094-8-90</pub-id>
<pub-id pub-id-type="pmid">21816039</pub-id></mixed-citation>
</ref>
<ref id="B98">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miklossy</surname><given-names>J.</given-names></name></person-group> (<year>2016</year>). <article-title>Bacterial amyloid and DNA are important constituents of senile plaques: further evidence of the spirochetal and biofilm nature of senile plaques.</article-title>
<source/><italic>J. Alzheimers Dis.</italic>
<volume>13</volume>
<fpage>1459</fpage>–<lpage>1473</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-160451</pub-id>
<pub-id pub-id-type="pmid">27314530</pub-id></mixed-citation>
</ref>
<ref id="B99">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minter</surname><given-names>M. R.</given-names></name><name><surname>Hinterleitner</surname><given-names>R.</given-names></name><name><surname>Meisel</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Leone</surname><given-names>V.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Antibiotic-induced perturbations in microbial diversity during post-natal development alters amyloid pathology in an aged APPSWE/PS1ΔE9 murine model of Alzheimer’s disease.</article-title>
<source/><italic>Sci. Rep.</italic>
<volume>7</volume>:<issue>10411</issue>.</mixed-citation>
</ref>
<ref id="B100">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minter</surname><given-names>M. R.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Leone</surname><given-names>V.</given-names></name><name><surname>Ringus</surname><given-names>D. L.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Oyler-Castrillo</surname><given-names>P.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer’s disease.</article-title>
<source/><italic>Sci. Rep.</italic>
<volume>21</volume>:<issue>30028</issue>.</mixed-citation>
</ref>
<ref id="B101">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moir</surname><given-names>R. D.</given-names></name><name><surname>Lathe</surname><given-names>R.</given-names></name><name><surname>Tanzi</surname><given-names>R. E.</given-names></name></person-group> (<year>2018</year>). <article-title>The antimicrobial protection hypothesis of Alzheimer’s disease.</article-title>
<source/><italic>Alzheimers Dement. J. Alzheimers Assoc.</italic>
<volume>14</volume>
<fpage>1602</fpage>–<lpage>1614</lpage>. <pub-id pub-id-type="doi">10.1016/j.jalz.2018.06.3040</pub-id>
<pub-id pub-id-type="pmid">30314800</pub-id></mixed-citation>
</ref>
<ref id="B102">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montagne</surname><given-names>A.</given-names></name><name><surname>Barnes</surname><given-names>S. R.</given-names></name><name><surname>Sweeney</surname><given-names>M. D.</given-names></name><name><surname>Halliday</surname><given-names>M. R.</given-names></name><name><surname>Sagare</surname><given-names>A. P.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Blood-brain barrier breakdown in the aging human hippocampus.</article-title>
<source/><italic>Neuron</italic>
<volume>85</volume>
<fpage>296</fpage>–<lpage>302</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2014.12.032</pub-id>
<pub-id pub-id-type="pmid">25611508</pub-id></mixed-citation>
</ref>
<ref id="B103">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montagne</surname><given-names>A.</given-names></name><name><surname>Nikolakopoulou</surname><given-names>A. M.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name><name><surname>Sagare</surname><given-names>A. P.</given-names></name><name><surname>Si</surname><given-names>G.</given-names></name><name><surname>Lazic</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Pericyte degeneration causes white matter dysfunction in the mouse central nervous system.</article-title>
<source/><italic>Nat. Med.</italic>
<volume>24</volume>
<fpage>326</fpage>–<lpage>337</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4482</pub-id>
<pub-id pub-id-type="pmid">29400711</pub-id></mixed-citation>
</ref>
<ref id="B104">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mruthinti</surname><given-names>S.</given-names></name><name><surname>Buccafusco</surname><given-names>J. J.</given-names></name><name><surname>Hill</surname><given-names>W. D.</given-names></name><name><surname>Waller</surname><given-names>J. L.</given-names></name><name><surname>Jackson</surname><given-names>T. W.</given-names></name><name><surname>Zamrini</surname><given-names>E. Y.</given-names></name><etal></etal></person-group> (<year>2004</year>). <article-title>Autoimmunity in Alzheimer’s disease: increased levels of circulating IgGs binding Abeta and RAGE peptides.</article-title>
<source/><italic>Neurobiol. Aging</italic>
<volume>25</volume>
<fpage>1023</fpage>–<lpage>1032</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2003.11.001</pub-id>
<pub-id pub-id-type="pmid">15212827</pub-id></mixed-citation>
</ref>
<ref id="B105">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myagkova</surname><given-names>M. A.</given-names></name><name><surname>Gavrilova</surname><given-names>S. I.</given-names></name><name><surname>Lermontova</surname><given-names>N. N.</given-names></name><name><surname>Kalyn</surname><given-names>Y. B.</given-names></name><name><surname>Selezneva</surname><given-names>N. D.</given-names></name><name><surname>Zharikov</surname><given-names>G. A.</given-names></name><etal></etal></person-group> (<year>2001</year>). <article-title>Autoantibodies to beta-amyloid and neurotransmitters in patients with Alzheimer’s disease and senile dementia of the Alzheimer type.</article-title>
<source/><italic>Bull. Exp. Biol. Med.</italic>
<volume>131</volume>
<fpage>127</fpage>–<lpage>129</lpage>. <pub-id pub-id-type="pmid">11391392</pub-id></mixed-citation>
</ref>
<ref id="B106">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myles</surname><given-names>I. A.</given-names></name></person-group> (<year>2014</year>). <article-title>Fast food fever: reviewing the impacts of the Western diet on immunity.</article-title>
<source/><italic>Nutr. J.</italic>
<volume>13</volume>:<issue>61</issue>. <pub-id pub-id-type="doi">10.1186/1475-2891-13-61</pub-id>
<pub-id pub-id-type="pmid">24939238</pub-id></mixed-citation>
</ref>
<ref id="B107">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Na</surname><given-names>W.</given-names></name><name><surname>Shin</surname><given-names>J. Y.</given-names></name><name><surname>Lee</surname><given-names>J. Y.</given-names></name><name><surname>Jeong</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>W.-S.</given-names></name><name><surname>Yune</surname><given-names>T. Y.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Dexamethasone suppresses JMJD3 gene activation via a putative negative glucocorticoid response element and maintains integrity of tight junctions in brain microvascular endothelial cells.</article-title>
<source/><italic>J. Cereb. Blood Flow Metab.</italic>
<volume>37</volume>
<fpage>3695</fpage>–<lpage>3708</lpage>. <pub-id pub-id-type="doi">10.1177/0271678X17701156</pub-id>
<pub-id pub-id-type="pmid">28338398</pub-id></mixed-citation>
</ref>
<ref id="B108">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nation</surname><given-names>D. A.</given-names></name><name><surname>Sweeney</surname><given-names>M. D.</given-names></name><name><surname>Montagne</surname><given-names>A.</given-names></name><name><surname>Sagare</surname><given-names>A. P.</given-names></name><name><surname>D’Orazio</surname><given-names>L. M.</given-names></name><name><surname>Pachicano</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction.</article-title>
<source/><italic>Nat. Med.</italic>
<volume>25</volume>
<fpage>270</fpage>–<lpage>276</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-018-0297-y</pub-id>
<pub-id pub-id-type="pmid">30643288</pub-id></mixed-citation>
</ref>
<ref id="B109">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikolakopoulou</surname><given-names>A. M.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name><name><surname>Montagne</surname><given-names>A.</given-names></name><name><surname>Zlokovic</surname><given-names>B. V.</given-names></name></person-group> (<year>2019</year>). <article-title>Regional early and progressive loss of brain pericytes but not vascular smooth muscle cells in adult mice with disrupted platelet-derived growth factor receptor-β signaling.</article-title>
<source/><italic>PLoS One</italic>
<volume>12</volume>:<issue>e0176225</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0176225</pub-id>
<pub-id pub-id-type="pmid">28441414</pub-id></mixed-citation>
</ref>
<ref id="B110">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>S.</given-names></name><name><surname>Manabe</surname><given-names>I.</given-names></name><name><surname>Takaki</surname><given-names>S.</given-names></name><name><surname>Nagasaki</surname><given-names>M.</given-names></name><name><surname>Otsu</surname><given-names>M.</given-names></name><name><surname>Yamashita</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Adipose natural regulatory B cells negatively control adipose tissue inflammation.</article-title>
<source/><italic>Cell Metab.</italic>
<volume>18</volume>
<fpage>759</fpage>–<lpage>766</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2013.09.017</pub-id>
<pub-id pub-id-type="pmid">24209772</pub-id></mixed-citation>
</ref>
<ref id="B111">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noé</surname><given-names>F. M.</given-names></name><name><surname>Marchi</surname><given-names>N.</given-names></name></person-group> (<year>2019</year>). <article-title>Central nervous system lymphatic unit, immunity, and epilepsy: is there a link?</article-title>
<source/><italic>Epilepsia Open</italic>
<volume>4</volume>
<fpage>30</fpage>–<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1002/epi4.12302</pub-id>
<pub-id pub-id-type="pmid">30868113</pub-id></mixed-citation>
</ref>
<ref id="B112">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nortley</surname><given-names>R.</given-names></name><name><surname>Korte</surname><given-names>N.</given-names></name><name><surname>Izquierdo</surname><given-names>P.</given-names></name><name><surname>Hirunpattarasilp</surname><given-names>C.</given-names></name><name><surname>Mishra</surname><given-names>A.</given-names></name><name><surname>Jaunmuktane</surname><given-names>Z.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Amyloid β oligomers constrict human capillaries in Alzheimer’s disease via signaling to pericytes.</article-title>
<source/><italic>Science</italic>
<volume>365</volume>:<issue>eaav9518</issue>. <pub-id pub-id-type="doi">10.1126/science.aav9518</pub-id>
<pub-id pub-id-type="pmid">31221773</pub-id></mixed-citation>
</ref>
<ref id="B113">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ochoa-Repáraz</surname><given-names>J.</given-names></name><name><surname>Mielcarz</surname><given-names>D. W.</given-names></name><name><surname>Ditrio</surname><given-names>L. E.</given-names></name><name><surname>Burroughs</surname><given-names>A. R.</given-names></name><name><surname>Foureau</surname><given-names>D. M.</given-names></name><name><surname>Haque-Begum</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis.</article-title>
<source/><italic>J. Immunol.</italic>
<volume>183</volume>
<fpage>6041</fpage>–<lpage>6050</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.0900747</pub-id>
<pub-id pub-id-type="pmid">19841183</pub-id></mixed-citation>
</ref>
<ref id="B114">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ochoa-Repáraz</surname><given-names>J.</given-names></name><name><surname>Mielcarz</surname><given-names>D. W.</given-names></name><name><surname>Haque-Begum</surname><given-names>S.</given-names></name><name><surname>Kasper</surname><given-names>L. H.</given-names></name></person-group> (<year>2010</year>). <article-title>Induction of a regulatory B cell population in experimental allergic encephalomyelitis by alteration of the gut commensal microflora.</article-title>
<source/><italic>Gut Microbes</italic>
<volume>1</volume>
<fpage>103</fpage>–<lpage>108</lpage>. <pub-id pub-id-type="doi">10.4161/gmic.1.2.11515</pub-id>
<pub-id pub-id-type="pmid">21326918</pub-id></mixed-citation>
</ref>
<ref id="B115">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Omalu</surname><given-names>B. I.</given-names></name><name><surname>Hamilton</surname><given-names>R. L.</given-names></name><name><surname>Kamboh</surname><given-names>M. I.</given-names></name><name><surname>DeKosky</surname><given-names>S. T.</given-names></name><name><surname>Bailes</surname><given-names>J.</given-names></name></person-group> (<year>2010</year>). <article-title>Chronic traumatic encephalopathy (CTE) in a National Football League Player: case report and emerging medicolegal practice questions.</article-title>
<source/><italic>J. Forensic Nurs.</italic>
<volume>6</volume>
<fpage>40</fpage>–<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1111/j.1939-3938.2009.01064.x</pub-id>
<pub-id pub-id-type="pmid">20201914</pub-id></mixed-citation>
</ref>
<ref id="B116">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouwehand</surname><given-names>A.</given-names></name><name><surname>Isolauri</surname><given-names>E.</given-names></name><name><surname>Salminen</surname><given-names>S.</given-names></name></person-group> (<year>2002</year>). <article-title>The role of the intestinal microflora for the development of the immune system in early childhood.</article-title>
<source/><italic>Eur. J. Nutr.</italic>
<volume>41</volume>(<issue>Suppl. 1</issue>), <fpage>I32</fpage>–<lpage>I37</lpage>. <pub-id pub-id-type="pmid">12420114</pub-id></mixed-citation>
</ref>
<ref id="B117">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pagliai</surname><given-names>G.</given-names></name><name><surname>Russo</surname><given-names>E.</given-names></name><name><surname>Niccolai</surname><given-names>E.</given-names></name><name><surname>Dinu</surname><given-names>M.</given-names></name><name><surname>Di Pilato</surname><given-names>V.</given-names></name><name><surname>Magrini</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Influence of a 3-month low-calorie Mediterranean diet compared to the vegetarian diet on human gut microbiota and SCFA: the CARDIVEG study.</article-title>
<source/><italic>Eur. J. Nutr.</italic>
<pub-id pub-id-type="doi">10.1007/s00394-019-02050-0</pub-id>
<comment>[Epub ahead of print]</comment>. <pub-id pub-id-type="pmid">31292752</pub-id></mixed-citation>
</ref>
<ref id="B118">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Païssé</surname><given-names>S.</given-names></name><name><surname>Valle</surname><given-names>C.</given-names></name><name><surname>Servant</surname><given-names>F.</given-names></name><name><surname>Courtney</surname><given-names>M.</given-names></name><name><surname>Burcelin</surname><given-names>R.</given-names></name><name><surname>Amar</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Comprehensive description of blood microbiome from healthy donors assessed by 16S targeted metagenomic sequencing.</article-title>
<source/><italic>Transfusion</italic>
<volume>56</volume>
<fpage>1138</fpage>–<lpage>1147</lpage>. <pub-id pub-id-type="doi">10.1111/trf.13477</pub-id>
<pub-id pub-id-type="pmid">26865079</pub-id></mixed-citation>
</ref>
<ref id="B119">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pani</surname><given-names>F.</given-names></name><name><surname>Di Dalmazi</surname><given-names>G.</given-names></name><name><surname>Corsello</surname><given-names>A.</given-names></name><name><surname>Oliver</surname><given-names>T. G.</given-names></name><name><surname>Livezey</surname><given-names>J. R.</given-names></name><name><surname>Caturegli</surname><given-names>P.</given-names></name></person-group> (<year>2019</year>). <article-title>MON-450 pituitary antibodies in a cohort of us service members with traumatic brain injury.</article-title>
<source/><italic>J. Endocr. Soc.</italic>
<volume>3</volume>(<issue>Suppl. 1</issue>):<fpage>MON</fpage>–<lpage>450</lpage>.</mixed-citation>
</ref>
<ref id="B120">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>A.</given-names></name><name><surname>Fonseca</surname><given-names>S.</given-names></name><name><surname>Carding</surname><given-names>S. R.</given-names></name></person-group> (<year>2019</year>). <article-title>Gut microbes and metabolites as modulators of blood-brain barrier integrity and brain health.</article-title>
<source/><italic>Gut Microbes</italic>
<pub-id pub-id-type="doi">10.1080/19490976.2019.1638722</pub-id>
<comment>[Epub ahead of print]</comment>. <pub-id pub-id-type="pmid">31368397</pub-id></mixed-citation>
</ref>
<ref id="B121">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavlov</surname><given-names>V. A.</given-names></name><name><surname>Tracey</surname><given-names>K. J.</given-names></name></person-group> (<year>2017</year>). <article-title>Neural regulation of immunity: molecular mechanisms and clinical translation.</article-title>
<source/><italic>Nat. Neurosci.</italic>
<volume>20</volume>
<fpage>156</fpage>–<lpage>166</lpage>. <pub-id pub-id-type="doi">10.1038/nn.4477</pub-id>
<pub-id pub-id-type="pmid">28092663</pub-id></mixed-citation>
</ref>
<ref id="B122">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pestka</surname><given-names>J. J.</given-names></name><name><surname>Vines</surname><given-names>L. L.</given-names></name><name><surname>Bates</surname><given-names>M. A.</given-names></name><name><surname>He</surname><given-names>K.</given-names></name><name><surname>Langohr</surname><given-names>I.</given-names></name></person-group> (<year>2014</year>). <article-title>Comparative effects of n-3, n-6 and n-9 unsaturated fatty acid-rich diet consumption on lupus nephritis, autoantibody production and CD4+ T cell-related gene responses in the autoimmune NZBWF1 mouse.</article-title>
<source/><italic>PLoS One</italic>
<volume>9</volume>:<issue>e100255</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0100255</pub-id>
<pub-id pub-id-type="pmid">24945254</pub-id></mixed-citation>
</ref>
<ref id="B123">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petta</surname><given-names>I.</given-names></name><name><surname>Fraussen</surname><given-names>J.</given-names></name><name><surname>Somers</surname><given-names>V.</given-names></name><name><surname>Kleinewietfeld</surname><given-names>M.</given-names></name></person-group> (<year>2018</year>). <article-title>Interrelation of diet, gut microbiome, and autoantibody production.</article-title>
<source/><italic>Front. Immunol.</italic>
<volume>9</volume>:<issue>439</issue>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.00439</pub-id>
<pub-id pub-id-type="pmid">29559977</pub-id></mixed-citation>
</ref>
<ref id="B124">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poole</surname><given-names>S.</given-names></name><name><surname>Singhrao</surname><given-names>S. K.</given-names></name><name><surname>Chukkapalli</surname><given-names>S.</given-names></name><name><surname>Rivera</surname><given-names>M.</given-names></name><name><surname>Velsko</surname><given-names>I.</given-names></name><name><surname>Kesavalu</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Active invasion of <italic>Porphyromonas gingivalis</italic> and infection-induced complement activation in ApoE-/- mice brains.</article-title>
<source/><italic>J. Alzheimers Dis.</italic>
<volume>43</volume>
<fpage>67</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-140315</pub-id>
<pub-id pub-id-type="pmid">25061055</pub-id></mixed-citation>
</ref>
<ref id="B125">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Posse de Chaves</surname><given-names>E.</given-names></name><name><surname>Sipione</surname><given-names>S.</given-names></name></person-group> (<year>2010</year>). <article-title>Sphingolipids and gangliosides of the nervous system in membrane function and dysfunction.</article-title>
<source/><italic>FEBS Lett.</italic>
<volume>584</volume>
<fpage>1748</fpage>–<lpage>1759</lpage>. <pub-id pub-id-type="doi">10.1016/j.febslet.2009.12.010</pub-id>
<pub-id pub-id-type="pmid">20006608</pub-id></mixed-citation>
</ref>
<ref id="B126">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prinz</surname><given-names>M.</given-names></name><name><surname>Priller</surname><given-names>J.</given-names></name></person-group> (<year>2017</year>). <article-title>The role of peripheral immune cells in the CNS in steady state and disease.</article-title>
<source/><italic>Nat. Neurosci.</italic>
<volume>20</volume>
<fpage>136</fpage>–<lpage>144</lpage>. <pub-id pub-id-type="doi">10.1038/nn.4475</pub-id>
<pub-id pub-id-type="pmid">28092660</pub-id></mixed-citation>
</ref>
<ref id="B127">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purvis</surname><given-names>G. S. D.</given-names></name><name><surname>Solito</surname><given-names>E.</given-names></name><name><surname>Thiemermann</surname><given-names>C.</given-names></name></person-group> (<year>2019</year>). <article-title>Annexin-A1: therapeutic potential in microvascular disease.</article-title>
<source/><italic>Front. Immunol.</italic>
<volume>10</volume>:<issue>938</issue>. <pub-id pub-id-type="doi">10.3389/fimmu.2019.00938</pub-id>
<pub-id pub-id-type="pmid">31114582</pub-id></mixed-citation>
</ref>
<ref id="B128">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>B.-X.</given-names></name><name><surname>Gong</surname><given-names>Y.</given-names></name><name><surname>Moore</surname><given-names>C.</given-names></name><name><surname>Fu</surname><given-names>M.</given-names></name><name><surname>German</surname><given-names>D. C.</given-names></name><name><surname>Chang</surname><given-names>L.-Y.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Beta-amyloid auto-antibodies are reduced in Alzheimer’s disease.</article-title>
<source/><italic>J. Neuroimmunol.</italic>
<volume>274</volume>
<fpage>168</fpage>–<lpage>173</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneuroim.2014.06.017</pub-id>
<pub-id pub-id-type="pmid">25022335</pub-id></mixed-citation>
</ref>
<ref id="B129">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raad</surname><given-names>M.</given-names></name><name><surname>Nohra</surname><given-names>E.</given-names></name><name><surname>Chams</surname><given-names>N.</given-names></name><name><surname>Itani</surname><given-names>M.</given-names></name><name><surname>Talih</surname><given-names>F.</given-names></name><name><surname>Mondello</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Autoantibodies in traumatic brain injury and central nervous system trauma.</article-title>
<source/><italic>Neuroscience</italic>
<volume>281</volume>
<fpage>16</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2014.08.045</pub-id>
<pub-id pub-id-type="pmid">25220901</pub-id></mixed-citation>
</ref>
<ref id="B130">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname><given-names>M. T.</given-names></name><name><surname>Ghosh</surname><given-names>C.</given-names></name><name><surname>Hossain</surname><given-names>M.</given-names></name><name><surname>Linfield</surname><given-names>D.</given-names></name><name><surname>Rezaee</surname><given-names>F.</given-names></name><name><surname>Janigro</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>IFN-γ, IL-17A, or zonulin rapidly increase the permeability of the blood-brain and small intestinal epithelial barriers: relevance for neuro-inflammatory diseases.</article-title>
<source/><italic>Biochem. Biophys. Res. Commun.</italic>
<volume>507</volume>
<fpage>274</fpage>–<lpage>279</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2018.11.021</pub-id>
<pub-id pub-id-type="pmid">30449598</pub-id></mixed-citation>
</ref>
<ref id="B131">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ransohoff</surname><given-names>R. M.</given-names></name></person-group> (<year>2016</year>). <article-title>How neuroinflammation contributes to neurodegeneration.</article-title>
<source/><italic>Science</italic>
<volume>353</volume>
<fpage>777</fpage>–<lpage>783</lpage>. <pub-id pub-id-type="doi">10.1126/science.aag2590</pub-id>
<pub-id pub-id-type="pmid">27540165</pub-id></mixed-citation>
</ref>
<ref id="B132">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Religa</surname><given-names>P.</given-names></name><name><surname>Cao</surname><given-names>R.</given-names></name><name><surname>Religa</surname><given-names>D.</given-names></name><name><surname>Xue</surname><given-names>Y.</given-names></name><name><surname>Bogdanovic</surname><given-names>N.</given-names></name><name><surname>Westaway</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>VEGF significantly restores impaired memory behavior in Alzheimer’s mice by improvement of vascular survival.</article-title>
<source/><italic>Sci. Rep.</italic>
<volume>3</volume>
<issue>2053</issue>.</mixed-citation>
</ref>
<ref id="B133">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reza</surname><given-names>M. M.</given-names></name><name><surname>Finlay</surname><given-names>B. B.</given-names></name><name><surname>Pettersson</surname><given-names>S.</given-names></name></person-group> (<year>2019</year>). <article-title>Gut microbes, ageing &amp; organ function: a chameleon in modern biology?</article-title>
<source/><italic>EMBO Mol. Med.</italic>
<volume>11</volume>:<issue>e9872</issue>.</mixed-citation>
</ref>
<ref id="B134">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rinne</surname><given-names>J. O.</given-names></name><name><surname>Brooks</surname><given-names>D. J.</given-names></name><name><surname>Rossor</surname><given-names>M. N.</given-names></name><name><surname>Fox</surname><given-names>N. C.</given-names></name><name><surname>Bullock</surname><given-names>R.</given-names></name><name><surname>Klunk</surname><given-names>W. E.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.</article-title>
<source/><italic>Lancet Neurol.</italic>
<volume>9</volume>
<fpage>363</fpage>–<lpage>372</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(10)70043-0</pub-id><pub-id pub-id-type="pmid">20189881</pub-id></mixed-citation>
</ref>
<ref id="B135">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenmann</surname><given-names>H.</given-names></name><name><surname>Meiner</surname><given-names>Z.</given-names></name><name><surname>Geylis</surname><given-names>V.</given-names></name><name><surname>Abramsky</surname><given-names>O.</given-names></name><name><surname>Steinitz</surname><given-names>M.</given-names></name></person-group> (<year>2006</year>). <article-title>Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer’s disease and healthy subjects.</article-title>
<source/><italic>Neurosci Lett.</italic>
<volume>410</volume>
<fpage>90</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2006.01.072</pub-id>
<pub-id pub-id-type="pmid">17095156</pub-id></mixed-citation>
</ref>
<ref id="B136">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudehill</surname><given-names>S.</given-names></name><name><surname>Muhallab</surname><given-names>S.</given-names></name><name><surname>Wennersten</surname><given-names>A.</given-names></name><name><surname>von Gertten</surname><given-names>C.</given-names></name><name><surname>Al Nimer</surname><given-names>F.</given-names></name><name><surname>Sandberg-Nordqvist</surname><given-names>A. C.</given-names></name><etal></etal></person-group> (<year>2006</year>). <article-title>Autoreactive antibodies against neurons and basal lamina found in serum following experimental brain contusion in rats.</article-title>
<source/><italic>Acta Neurochir.</italic>
<volume>148</volume>
<fpage>199</fpage>–<lpage>205</lpage>. <pub-id pub-id-type="doi">10.1007/s00701-005-0673-5</pub-id>
<pub-id pub-id-type="pmid">16362182</pub-id></mixed-citation>
</ref>
<ref id="B137">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rustenhoven</surname><given-names>J.</given-names></name><name><surname>Jansson</surname><given-names>D.</given-names></name><name><surname>Smyth</surname><given-names>L. C.</given-names></name><name><surname>Dragunow</surname><given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>Brain Pericytes As Mediators of Neuroinflammation.</article-title>
<source/><italic>Trends Pharmacol. Sci.</italic>
<volume>38</volume>
<fpage>291</fpage>–<lpage>304</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2016.12.001</pub-id>
<pub-id pub-id-type="pmid">28017362</pub-id></mixed-citation>
</ref>
<ref id="B138">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salloway</surname><given-names>S.</given-names></name><name><surname>Sperling</surname><given-names>R.</given-names></name><name><surname>Gilman</surname><given-names>S.</given-names></name><name><surname>Fox</surname><given-names>N. C.</given-names></name><name><surname>Blennow</surname><given-names>K.</given-names></name><name><surname>Raskind</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.</article-title>
<source/><italic>Neurology</italic>
<volume>73</volume>
<fpage>2061</fpage>–<lpage>2070</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0b013e3181c67808</pub-id>
<pub-id pub-id-type="pmid">19923550</pub-id></mixed-citation>
</ref>
<ref id="B139">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sampson</surname><given-names>T. R.</given-names></name><name><surname>Debelius</surname><given-names>J. W.</given-names></name><name><surname>Thron</surname><given-names>T.</given-names></name><name><surname>Janssen</surname><given-names>S.</given-names></name><name><surname>Shastri</surname><given-names>G. G.</given-names></name><name><surname>Ilhan</surname><given-names>Z. E.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease.</article-title>
<source/><italic>Cell</italic>
<volume>167</volume>
<fpage>1469.e12</fpage>–<lpage>1480.e12</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2016.11.018</pub-id>
<pub-id pub-id-type="pmid">27912057</pub-id></mixed-citation>
</ref>
<ref id="B140">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheperjans</surname><given-names>F.</given-names></name><name><surname>Aho</surname><given-names>V.</given-names></name><name><surname>Pereira</surname><given-names>P. A. B.</given-names></name><name><surname>Koskinen</surname><given-names>K.</given-names></name><name><surname>Paulin</surname><given-names>L.</given-names></name><name><surname>Pekkonen</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Gut microbiota are related to Parkinson’s disease and clinical phenotype.</article-title>
<source/><italic>Mov. Disord.</italic>
<volume>30</volume>
<fpage>350</fpage>–<lpage>358</lpage>.<pub-id pub-id-type="pmid">25476529</pub-id></mixed-citation>
</ref>
<ref id="B141">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schierwagen</surname><given-names>R.</given-names></name><name><surname>Alvarez-Silva</surname><given-names>C.</given-names></name><name><surname>Madsen</surname><given-names>M. S. A.</given-names></name><name><surname>Kolbe</surname><given-names>C. C.</given-names></name><name><surname>Meyer</surname><given-names>C.</given-names></name><name><surname>Thomas</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Circulating microbiome in blood of different circulatory compartments.</article-title>
<source/><italic>Gut</italic>
<pub-id pub-id-type="doi">10.1136/gutjnl-2018-316227</pub-id>
<comment>[Epub ahead of print]</comment>. <pub-id pub-id-type="pmid">29581241</pub-id></mixed-citation>
</ref>
<ref id="B142">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schroeder</surname><given-names>B. O.</given-names></name><name><surname>Bäckhed</surname><given-names>F.</given-names></name></person-group> (<year>2016</year>). <article-title>Signals from the gut microbiota to distant organs in physiology and disease.</article-title>
<source/><italic>Nat. Med.</italic>
<volume>22</volume>
<fpage>1079</fpage>–<lpage>1089</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4185</pub-id>
<pub-id pub-id-type="pmid">27711063</pub-id></mixed-citation>
</ref>
<ref id="B143">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>M.</given-names></name><name><surname>Shechter</surname><given-names>R.</given-names></name></person-group> (<year>2010</year>). <article-title>Systemic inflammatory cells fight off neurodegenerative disease.</article-title>
<source/><italic>Nat. Rev. Neurol.</italic>
<volume>6</volume>
<fpage>405</fpage>–<lpage>410</lpage>. <pub-id pub-id-type="doi">10.1038/nrneurol.2010.71</pub-id>
<pub-id pub-id-type="pmid">20531383</pub-id></mixed-citation>
</ref>
<ref id="B144">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senatorov</surname><given-names>V. V.</given-names></name><name><surname>Friedman</surname><given-names>A. R.</given-names></name><name><surname>Milikovsky</surname><given-names>D. Z.</given-names></name><name><surname>Ofer</surname><given-names>J.</given-names></name><name><surname>Saar-Ashkenazy</surname><given-names>R.</given-names></name><name><surname>Charbash</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Blood-brain barrier dysfunction in aging induces hyper-activation of TGF-beta signaling and chronic yet reversible neural dysfunction.</article-title>
<source/><italic>Sci. Transl. Med.</italic>
<volume>11</volume>:<issue>eaaw8283</issue>. <pub-id pub-id-type="doi">10.1126/scitranslmed.aaw8283</pub-id>
<pub-id pub-id-type="pmid">31801886</pub-id></mixed-citation>
</ref>
<ref id="B145">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sevigny</surname><given-names>J.</given-names></name><name><surname>Chiao</surname><given-names>P.</given-names></name><name><surname>Bussière</surname><given-names>T.</given-names></name><name><surname>Weinreb</surname><given-names>P. H.</given-names></name><name><surname>Williams</surname><given-names>L.</given-names></name><name><surname>Maier</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease.</article-title>
<source/><italic>Nature</italic>
<volume>01</volume>
<fpage>50</fpage>–<lpage>56</lpage>.</mixed-citation>
</ref>
<ref id="B146">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shanahan</surname><given-names>F.</given-names></name><name><surname>van Sinderen</surname><given-names>D.</given-names></name><name><surname>O’Toole</surname><given-names>P. W.</given-names></name><name><surname>Stanton</surname><given-names>C.</given-names></name></person-group> (<year>2017</year>). <article-title>Feeding the microbiota: transducer of nutrient signals for the host.</article-title>
<source/><italic>Gut</italic>
<volume>66</volume>
<fpage>1709</fpage>–<lpage>1717</lpage>. <pub-id pub-id-type="doi">10.1136/gutjnl-2017-313872</pub-id>
<pub-id pub-id-type="pmid">28663354</pub-id></mixed-citation>
</ref>
<ref id="B147">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherwin</surname><given-names>E.</given-names></name><name><surname>Bordenstein</surname><given-names>S. R.</given-names></name><name><surname>Quinn</surname><given-names>J. L.</given-names></name><name><surname>Dinan</surname><given-names>T. G.</given-names></name><name><surname>Cryan</surname><given-names>J. F.</given-names></name></person-group> (<year>2019</year>). <article-title>Microbiota and the social brain.</article-title>
<source/><italic>Science</italic>
<volume>366</volume>:<issue>eaar2016</issue>.</mixed-citation>
</ref>
<ref id="B148">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sigurdsson</surname><given-names>E. M.</given-names></name></person-group> (<year>2018</year>). <article-title>Tau immunotherapies for Alzheimer’s disease and related tauopathies: progress and potential pitfalls.</article-title>
<source/><italic>J. Alzheimers Dis.</italic>
<volume>64</volume>(<issue>Suppl.1</issue>), <fpage>S555</fpage>–<lpage>S565</lpage>.<pub-id pub-id-type="pmid">29865056</pub-id></mixed-citation>
</ref>
<ref id="B149">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>R. K.</given-names></name><name><surname>Chang</surname><given-names>H.-W.</given-names></name><name><surname>Yan</surname><given-names>D.</given-names></name><name><surname>Lee</surname><given-names>K. M.</given-names></name><name><surname>Ucmak</surname><given-names>D.</given-names></name><name><surname>Wong</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Influence of diet on the gut microbiome and implications for human health.</article-title>
<source/><italic>J. Transl. Med.</italic>
<volume>15</volume>:<issue>73</issue>. <pub-id pub-id-type="doi">10.1186/s12967-017-1175-y</pub-id>
<pub-id pub-id-type="pmid">28388917</pub-id></mixed-citation>
</ref>
<ref id="B150">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinha</surname><given-names>R. K.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Burnier</surname><given-names>L.</given-names></name><name><surname>Gupta</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>PAR1 biased signaling is required for activated protein C <italic>in vivo</italic> benefits in sepsis and stroke.</article-title>
<source/><italic>Blood</italic>
<volume>15</volume>
<fpage>1163</fpage>–<lpage>1171</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2017-10-810895</pub-id>
<pub-id pub-id-type="pmid">29343482</pub-id></mixed-citation>
</ref>
<ref id="B151">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>C.</given-names></name><name><surname>Graham</surname><given-names>D. I.</given-names></name><name><surname>Murray</surname><given-names>L. S.</given-names></name><name><surname>Nicoll</surname><given-names>J. A.</given-names></name></person-group> (<year>2003</year>). <article-title>Tau immunohistochemistry in acute brain injury.</article-title>
<source/><italic>Neuropathol. Appl. Neurobiol.</italic>
<volume>29</volume>
<fpage>496</fpage>–<lpage>502</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2990.2003.00488.x</pub-id>
<pub-id pub-id-type="pmid">14507341</pub-id></mixed-citation>
</ref>
<ref id="B152">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sommer</surname><given-names>A.</given-names></name><name><surname>Winner</surname><given-names>B.</given-names></name><name><surname>Prots</surname><given-names>I.</given-names></name></person-group> (<year>2017</year>). <article-title>The Trojan horse - neuroinflammatory impact of T cells in neurodegenerative diseases.</article-title>
<source/><italic>Mol. Neurodegener.</italic>
<volume>12</volume>:<issue>78</issue>. <pub-id pub-id-type="doi">10.1186/s13024-017-0222-8</pub-id>
<pub-id pub-id-type="pmid">29078813</pub-id></mixed-citation>
</ref>
<ref id="B153">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorokina</surname><given-names>E. G.</given-names></name><name><surname>Vol’pina</surname><given-names>O. M.</given-names></name><name><surname>Semenova</surname><given-names>Z. B.</given-names></name><name><surname>Karaseva</surname><given-names>O. V.</given-names></name><name><surname>Koroev</surname><given-names>D. O.</given-names></name><name><surname>Kamynina</surname><given-names>A. V.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>[Autoantibodies to α7-subunit of neuronal acetylcholine receptor in children with traumatic brain injury].</article-title>
<source/><italic>Zh. Nevrol. Psikhiatr. Im. S S Korsakova</italic>
<volume>111</volume>
<fpage>56</fpage>–<lpage>60</lpage>.</mixed-citation>
</ref>
<ref id="B154">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soscia</surname><given-names>S. J.</given-names></name><name><surname>Kirby</surname><given-names>J. E.</given-names></name><name><surname>Washicosky</surname><given-names>K. J.</given-names></name><name><surname>Tucker</surname><given-names>S. M.</given-names></name><name><surname>Ingelsson</surname><given-names>M.</given-names></name><name><surname>Hyman</surname><given-names>B.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>The Alzheimer’s disease-associated amyloid beta-protein is an antimicrobial peptide.</article-title>
<source/><italic>PLoS One</italic>
<volume>5</volume>:<issue>e9505</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0009505</pub-id>
<pub-id pub-id-type="pmid">20209079</pub-id></mixed-citation>
</ref>
<ref id="B155">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>E. J.</given-names></name><name><surname>Fredriksson</surname><given-names>L.</given-names></name><name><surname>Kanzawa</surname><given-names>M.</given-names></name><name><surname>Moore</surname><given-names>S.</given-names></name><name><surname>Folestad</surname><given-names>E.</given-names></name><name><surname>Stevenson</surname><given-names>T. K.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Imatinib treatment reduces brain injury in a murine model of traumatic brain injury.</article-title>
<source/><italic>Front. Cell. Neurosci.</italic>
<volume>9</volume>:<issue>385</issue>. <pub-id pub-id-type="doi">10.3389/fncel.2015.00385</pub-id>
<pub-id pub-id-type="pmid">26500491</pub-id></mixed-citation>
</ref>
<ref id="B156">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sweeney</surname><given-names>M. D.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name><name><surname>Montagne</surname><given-names>A.</given-names></name><name><surname>Nelson</surname><given-names>A. R.</given-names></name><name><surname>Zlokovic</surname><given-names>B. V.</given-names></name></person-group> (<year>2019</year>). <article-title>Blood-brain barrier: from physiology to disease and back.</article-title>
<source/><italic>Physiol. Rev.</italic>
<volume>01</volume>
<fpage>21</fpage>–<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00050.2017</pub-id>
<pub-id pub-id-type="pmid">30280653</pub-id></mixed-citation>
</ref>
<ref id="B157">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tai</surname><given-names>X. Y.</given-names></name><name><surname>Koepp</surname><given-names>M.</given-names></name><name><surname>Duncan</surname><given-names>J. S.</given-names></name><name><surname>Fox</surname><given-names>N.</given-names></name><name><surname>Thompson</surname><given-names>P.</given-names></name><name><surname>Baxendale</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Hyperphosphorylated tau in patients with refractory epilepsy correlates with cognitive decline: a study of temporal lobe resections.</article-title>
<source/><italic>Brain J. Neurol.</italic>
<volume>139</volume>(<issue>Pt 9</issue>), <fpage>2441</fpage>–<lpage>2455</lpage>. <pub-id pub-id-type="doi">10.1093/brain/aww187</pub-id>
<pub-id pub-id-type="pmid">27497924</pub-id></mixed-citation>
</ref>
<ref id="B158">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>J.</given-names></name><name><surname>Nakamura</surname><given-names>K.</given-names></name><name><surname>Takeda</surname><given-names>M.</given-names></name><name><surname>Tada</surname><given-names>K.</given-names></name><name><surname>Suzuki</surname><given-names>H.</given-names></name><name><surname>Morita</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>1989</year>). <article-title>Enzyme-linked immunosorbent assay for human autoantibody to glial fibrillary acidic protein: higher titer of the antibody is detected in serum of patients with Alzheimer’s disease.</article-title>
<source/><italic>Acta Neurol. Scand.</italic>
<volume>80</volume>
<fpage>554</fpage>–<lpage>560</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-0404.1989.tb03926.x</pub-id>
<pub-id pub-id-type="pmid">2618583</pub-id></mixed-citation>
</ref>
<ref id="B159">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanriverdi</surname><given-names>F.</given-names></name><name><surname>De Bellis</surname><given-names>A.</given-names></name><name><surname>Battaglia</surname><given-names>M.</given-names></name><name><surname>Bellastella</surname><given-names>G.</given-names></name><name><surname>Bizzarro</surname><given-names>A.</given-names></name><name><surname>Sinisi</surname><given-names>A. A.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Investigation of antihypothalamus and antipituitary antibodies in amateur boxers: is chronic repetitive head trauma-induced pituitary dysfunction associated with autoimmunity?</article-title>
<source/><italic>Eur. J. Endocrinol.</italic>
<volume>162</volume>
<fpage>861</fpage>–<lpage>867</lpage>. <pub-id pub-id-type="doi">10.1530/EJE-09-1024</pub-id>
<pub-id pub-id-type="pmid">20176736</pub-id></mixed-citation>
</ref>
<ref id="B160">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanriverdi</surname><given-names>F.</given-names></name><name><surname>De Bellis</surname><given-names>A.</given-names></name><name><surname>Bizzarro</surname><given-names>A.</given-names></name><name><surname>Sinisi</surname><given-names>A. A.</given-names></name><name><surname>Bellastella</surname><given-names>G.</given-names></name><name><surname>Pane</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Antipituitary antibodies after traumatic brain injury: is head trauma-induced pituitary dysfunction associated with autoimmunity?</article-title>
<source/><italic>Eur. J. Endocrinol.</italic>
<volume>159</volume>
<fpage>7</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1530/EJE-08-0050</pub-id>
<pub-id pub-id-type="pmid">18463108</pub-id></mixed-citation>
</ref>
<ref id="B161">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanriverdi</surname><given-names>F.</given-names></name><name><surname>Senyurek</surname><given-names>H.</given-names></name><name><surname>Unluhizarci</surname><given-names>K.</given-names></name><name><surname>Selcuklu</surname><given-names>A.</given-names></name><name><surname>Casanueva</surname><given-names>F. F.</given-names></name><name><surname>Kelestimur</surname><given-names>F.</given-names></name></person-group> (<year>2006</year>). <article-title>High risk of hypopituitarism after traumatic brain injury: a prospective investigation of anterior pituitary function in the acute phase and 12 months after trauma.</article-title>
<source/><italic>J. Clin. Endocrinol. Metab.</italic>
<volume>91</volume>
<fpage>2105</fpage>–<lpage>2111</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2005-2476</pub-id>
<pub-id pub-id-type="pmid">16522687</pub-id></mixed-citation>
</ref>
<ref id="B162">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiyagarajan</surname><given-names>M.</given-names></name><name><surname>Fernández</surname><given-names>J. A.</given-names></name><name><surname>Lane</surname><given-names>S. M.</given-names></name><name><surname>Griffin</surname><given-names>J. H.</given-names></name><name><surname>Zlokovic</surname><given-names>B. V.</given-names></name></person-group> (<year>2008</year>). <article-title>Activated protein C promotes neovascularization and neurogenesis in postischemic brain via protease-activated receptor 1.</article-title>
<source/><italic>J. Neurosci.</italic>
<volume>28</volume>
<fpage>12788</fpage>–<lpage>12797</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3485-08.2008</pub-id>
<pub-id pub-id-type="pmid">19036971</pub-id></mixed-citation>
</ref>
<ref id="B163">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>T.</given-names></name><name><surname>Thomas</surname><given-names>G.</given-names></name><name><surname>McLendon</surname><given-names>C.</given-names></name><name><surname>Sutton</surname><given-names>T.</given-names></name><name><surname>Mullan</surname><given-names>M.</given-names></name></person-group> (<year>1996</year>). <article-title>beta-Amyloid-mediated vasoactivity and vascular endothelial damage.</article-title>
<source/><italic>Nature</italic>
<volume>380</volume>
<fpage>168</fpage>–<lpage>171</lpage>. <pub-id pub-id-type="doi">10.1038/380168a0</pub-id>
<pub-id pub-id-type="pmid">8600393</pub-id></mixed-citation>
</ref>
<ref id="B164">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomasdottir</surname><given-names>V.</given-names></name><name><surname>Thorleifsdottir</surname><given-names>S.</given-names></name><name><surname>Vikingsson</surname><given-names>A.</given-names></name><name><surname>Hardardottir</surname><given-names>I.</given-names></name><name><surname>Freysdottir</surname><given-names>J.</given-names></name></person-group> (<year>2014</year>). <article-title>Dietary omega-3 fatty acids enhance the B1 but not the B2 cell immune response in mice with antigen-induced peritonitis.</article-title>
<source/><italic>J. Nutr. Biochem.</italic>
<volume>25</volume>
<fpage>111</fpage>–<lpage>117</lpage>. <pub-id pub-id-type="doi">10.1016/j.jnutbio.2013.09.010</pub-id>
<pub-id pub-id-type="pmid">24332949</pub-id></mixed-citation>
</ref>
<ref id="B165">
<mixed-citation publication-type="journal"><collab>U.S. National Library of Medicine</collab> (<year>2019a</year>). <source/><italic>A Long-Term Safety and Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients.</italic> Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00998764">https://clinicaltrials.gov/ct2/show/NCT00998764</ext-link></mixed-citation>
</ref>
<ref id="B166">
<mixed-citation publication-type="journal"><collab>U.S. National Library of Medicine</collab> (<year>2019b</year>). <source/><italic>A Long-Term Safety and Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients 2019.</italic> Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00996918">https://clinicaltrials.gov/ct2/show/NCT00996918</ext-link></mixed-citation>
</ref>
<ref id="B167">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vacirca</surname><given-names>D.</given-names></name><name><surname>Delunardo</surname><given-names>F.</given-names></name><name><surname>Matarrese</surname><given-names>P.</given-names></name><name><surname>Colasanti</surname><given-names>T.</given-names></name><name><surname>Margutti</surname><given-names>P.</given-names></name><name><surname>Siracusano</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Autoantibodies to the adenosine triphosphate synthase play a pathogenetic role in Alzheimer’s disease.</article-title>
<source/><italic>Neurobiol. Aging</italic>
<volume>33</volume>
<fpage>753</fpage>–<lpage>766</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2010.05.013</pub-id>
<pub-id pub-id-type="pmid">20594618</pub-id></mixed-citation>
</ref>
<ref id="B168">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Skike</surname><given-names>C. E.</given-names></name><name><surname>Jahrling</surname><given-names>J. B.</given-names></name><name><surname>Olson</surname><given-names>A. B.</given-names></name><name><surname>Sayre</surname><given-names>N. L.</given-names></name><name><surname>Hussong</surname><given-names>S. A.</given-names></name><name><surname>Ungvari</surname><given-names>Z.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer’s disease and vascular cognitive impairment.</article-title>
<source/><italic>Am. J. Physiol. Heart Circ. Physiol.</italic>
<volume>314</volume>
<fpage>H693</fpage>–<lpage>H703</lpage>.<pub-id pub-id-type="pmid">29351469</pub-id></mixed-citation>
</ref>
<ref id="B169">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vezzani</surname><given-names>A.</given-names></name><name><surname>French</surname><given-names>J.</given-names></name><name><surname>Bartfai</surname><given-names>T.</given-names></name><name><surname>Baram</surname><given-names>T. Z.</given-names></name></person-group> (<year>2011</year>). <article-title>The role of inflammation in epilepsy.</article-title>
<source/><italic>Nat. Rev. Neurol.</italic>
<volume>7</volume>
<fpage>31</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">21135885</pub-id></mixed-citation>
</ref>
<ref id="B170">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Virtue</surname><given-names>A. T.</given-names></name><name><surname>McCright</surname><given-names>S. J.</given-names></name><name><surname>Wright</surname><given-names>J. M.</given-names></name><name><surname>Jimenez</surname><given-names>M. T.</given-names></name><name><surname>Mowel</surname><given-names>W. K.</given-names></name><name><surname>Kotzin</surname><given-names>J. J.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>The gut microbiota regulates white adipose tissue inflammation and obesity via a family of microRNAs.</article-title>
<source/><italic>Sci. Transl. Med.</italic>
<volume>11</volume>:<issue>eaav1892</issue>. <pub-id pub-id-type="doi">10.1126/scitranslmed.aav1892</pub-id>
<pub-id pub-id-type="pmid">31189717</pub-id></mixed-citation>
</ref>
<ref id="B171">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogt</surname><given-names>N. M.</given-names></name><name><surname>Kerby</surname><given-names>R. L.</given-names></name><name><surname>Dill-McFarland</surname><given-names>K. A.</given-names></name><name><surname>Harding</surname><given-names>S. J.</given-names></name><name><surname>Merluzzi</surname><given-names>A. P.</given-names></name><name><surname>Johnson</surname><given-names>S. C.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Gut microbiome alterations in Alzheimer’s disease.</article-title>
<source/><italic>Sci. Rep.</italic>
<volume>7</volume>:<issue>13537</issue>. <pub-id pub-id-type="doi">10.1242/dmm.041947</pub-id>
<pub-id pub-id-type="pmid">31597644</pub-id></mixed-citation>
</ref>
<ref id="B172">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Sun</surname><given-names>G.</given-names></name><name><surname>Feng</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression.</article-title>
<source/><italic>Cell Res.</italic>
<volume>29</volume>
<fpage>787</fpage>–<lpage>803</lpage>. <pub-id pub-id-type="doi">10.1038/s41422-019-0216-x</pub-id>
<pub-id pub-id-type="pmid">31488882</pub-id></mixed-citation>
</ref>
<ref id="B173">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name><name><surname>Rege</surname><given-names>S. V.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Si</surname><given-names>G.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>3K3A-activated protein C stimulates postischemic neuronal repair by human neural stem cells in mice.</article-title>
<source/><italic>Nat. Med.</italic>
<volume>22</volume>
<fpage>1050</fpage>–<lpage>1055</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4154</pub-id>
<pub-id pub-id-type="pmid">27548576</pub-id></mixed-citation>
</ref>
<ref id="B174">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weksler</surname><given-names>M. E.</given-names></name><name><surname>Relkin</surname><given-names>N.</given-names></name><name><surname>Turkenich</surname><given-names>R.</given-names></name><name><surname>LaRusse</surname><given-names>S.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Szabo</surname><given-names>P.</given-names></name></person-group> (<year>2002</year>). <article-title>Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals.</article-title>
<source/><italic>Exp. Gerontol.</italic>
<volume>37</volume>
<fpage>943</fpage>–<lpage>948</lpage>. <pub-id pub-id-type="doi">10.1016/s0531-5565(02)00029-3</pub-id>
<pub-id pub-id-type="pmid">12086704</pub-id></mixed-citation>
</ref>
<ref id="B175">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>J. S.</given-names></name><name><surname>vainti</surname><given-names>S.</given-names></name><name><surname>Buccafusco</surname><given-names>J. J.</given-names></name><name><surname>Schade</surname><given-names>R. F.</given-names></name><name><surname>Mitchell</surname><given-names>M. B.</given-names></name><name><surname>Harrell</surname><given-names>D. U.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Anti-RAGE and Abeta immunoglobulin levels are related to dementia level and cognitive performance.</article-title>
<source/><italic>J. Gerontol. A Biol. Sci. Med. Sci.</italic>
<volume>64</volume>
<fpage>264</fpage>–<lpage>271</lpage>. <pub-id pub-id-type="doi">10.1093/gerona/gln002</pub-id>
<pub-id pub-id-type="pmid">19196906</pub-id></mixed-citation>
</ref>
<ref id="B176">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name></person-group> (<year>2016</year>). <article-title>Autoantibodies in Alzheimer’s disease: potential biomarkers, pathogenic roles, and therapeutic implications.</article-title>
<source/><italic>J. Biomed. Res.</italic>
<volume>30</volume>
<fpage>361</fpage>–<lpage>372</lpage>.<pub-id pub-id-type="pmid">27476881</pub-id></mixed-citation>
</ref>
<ref id="B177">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Eckman</surname><given-names>C.</given-names></name><name><surname>Younkin</surname><given-names>S.</given-names></name><name><surname>Hsiao</surname><given-names>K. K.</given-names></name><name><surname>Iadecola</surname><given-names>C.</given-names></name></person-group> (<year>1997</year>). <article-title>Increased susceptibility to ischemic brain damage in transgenic mice overexpressing the amyloid precursor protein.</article-title>
<source/><italic>J. Neurosci.</italic>
<volume>17</volume>
<fpage>7655</fpage>–<lpage>7661</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.17-20-07655.1997</pub-id><pub-id pub-id-type="pmid">9315887</pub-id></mixed-citation>
</ref>
<ref id="B178">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>N.</given-names></name><name><surname>Yin</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Gong</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>N.</given-names></name><name><surname>Fang</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Crystal structure and biochemical characterization of an aminopeptidase LapB from <italic>Legionella pneumophila</italic>.</article-title>
<source/><italic>J. Agric. Food Chem.</italic>
<volume>65</volume>
<fpage>7569</fpage>–<lpage>7578</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jafc.7b02849</pub-id>
<pub-id pub-id-type="pmid">28776986</pub-id></mixed-citation>
</ref>
<ref id="B179">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Zoltewicz</surname><given-names>J. S.</given-names></name><name><surname>Mondello</surname><given-names>S.</given-names></name><name><surname>Newsom</surname><given-names>K. J.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Human traumatic brain injury induces autoantibody response against glial fibrillary acidic protein and its breakdown products.</article-title>
<source/><italic>PLoS One</italic>
<volume>9</volume>:<issue>e92698</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0092698</pub-id>
<pub-id pub-id-type="pmid">24667434</pub-id></mixed-citation>
</ref>
<ref id="B180">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>P.</given-names></name><name><surname>Zeng</surname><given-names>B.</given-names></name><name><surname>Zhou</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Fang</surname><given-names>Z.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host’s metabolism.</article-title>
<source/><italic>Mol. Psychiatry</italic>
<volume>21</volume>
<fpage>786</fpage>–<lpage>796</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2016.44</pub-id>
<pub-id pub-id-type="pmid">27067014</pub-id></mixed-citation>
</ref>
<ref id="B181">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>Z.</given-names></name><name><surname>Ilieva</surname><given-names>H.</given-names></name><name><surname>Hallagan</surname><given-names>L.</given-names></name><name><surname>Bell</surname><given-names>R.</given-names></name><name><surname>Singh</surname><given-names>I.</given-names></name><name><surname>Paquette</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells.</article-title>
<source/><italic>J. Clin. Invest.</italic>
<volume>119</volume>
<fpage>3437</fpage>–<lpage>3449</lpage>. <pub-id pub-id-type="doi">10.1172/JCI38476</pub-id>
<pub-id pub-id-type="pmid">19841542</pub-id></mixed-citation>
</ref>
<ref id="B182">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhuang</surname><given-names>Z.-Q.</given-names></name><name><surname>Shen</surname><given-names>L.-L.</given-names></name><name><surname>Li</surname><given-names>W.-W.</given-names></name><name><surname>Fu</surname><given-names>X.</given-names></name><name><surname>Zeng</surname><given-names>F.</given-names></name><name><surname>Gui</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Gut microbiota is altered in patients with Alzheimer’s disease.</article-title>
<source/><italic>J. Alzheimers Dis.</italic>
<volume>63</volume>
<fpage>1337</fpage>–<lpage>1346</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-180176</pub-id>
<pub-id pub-id-type="pmid">29758946</pub-id></mixed-citation>
</ref>
<ref id="B183">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zlokovic</surname><given-names>B. V.</given-names></name></person-group> (<year>2008</year>). <article-title>The blood-brain barrier in health and chronic neurodegenerative disorders.</article-title>
<source/><italic>Neuron</italic>
<volume>57</volume>
<fpage>178</fpage>–<lpage>201</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2008.01.003</pub-id>
<pub-id pub-id-type="pmid">18215617</pub-id></mixed-citation>
</ref>
<ref id="B184">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zlokovic</surname><given-names>B. V.</given-names></name></person-group> (<year>2011</year>). <article-title>Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders.</article-title>
<source/><italic>Nat. Rev. Neurosci.</italic>
<volume>12</volume>
<fpage>723</fpage>–<lpage>738</lpage>. <pub-id pub-id-type="doi">10.1038/nrn3114</pub-id>
<pub-id pub-id-type="pmid">22048062</pub-id></mixed-citation>
</ref>
<ref id="B185">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zub</surname><given-names>E.</given-names></name><name><surname>Canet</surname><given-names>G.</given-names></name><name><surname>Garbelli</surname><given-names>R.</given-names></name><name><surname>Blaquiere</surname><given-names>M.</given-names></name><name><surname>Rossini</surname><given-names>L.</given-names></name><name><surname>Pastori</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>The GR-ANXA1 pathway is a pathological player and a candidate target in epilepsy.</article-title>
<source/><italic>FASEB J.</italic>
<volume>33</volume>
<fpage>13998</fpage>–<lpage>14009</lpage>. <pub-id pub-id-type="doi">10.1096/fj.201901596R</pub-id>
<pub-id pub-id-type="pmid">31618599</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>